CELLS FOR TREATING CANCER

Abstract

The invention relates to a method for determining the suitability of a granulocyte for treating cancer. The invention also relates to said granulocytes, methods for identifying said granulocytes and stem cells capable of differentiating into said granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

Claims

1. A method for determining the suitability of a granulocyte for treating cancer, the method comprising: a. comparing a measured expression level of one or more genes by the granulocyte, wherein the one or more genes are associated with suitability for treating cancer and are selected from: GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8, COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PPP3CB, ANXA1, PERM, PLEC, ACSL1, RAC1, and PSMB2, with the expression level of the same one or more genes in a reference standard; and b. determining the suitability of the granulocyte for treating cancer based on the comparison.

2. A method for identifying whether or not a donor produces granulocytes suitable for treating cancer, the method comprising: a. comparing a measured expression level of one or more genes by a granulocyte comprised in a sample obtainable from the donor, wherein the one or more genes are associated with suitability for treating cancer and are selected from: GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PPP3CB, ANXA1, PERM, PLEC, ACSL1, RAC1, and PSMB2, with the expression level of the same one or more genes in a reference standard; and b. identifying whether or not the donor produces granulocytes suitable for treating cancer based on the comparison.

3. The method according to claim 1 or 2, wherein step b. comprises: determining that the granulocyte is suitable for treating cancer or identifying that the donor produces granulocytes suitable for treating cancer when: i. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is increased when compared to the reference standard when the reference standard is from a granulocyte unsuitable for treating cancer; or ii. the measured expression level of ANXA1 and/or PPP3CB is decreased when compared to the reference standard, when the reference standard is from a granulocyte unsuitable for treating cancer; or iii. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is increased or the same when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer; or iv. the measured expression level of ANXA1 and/or PPP3CB is decreased or the same when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer; or determining that the granulocyte is unsuitable for treating cancer or identifying that the donor produces granulocytes that are unsuitable for treating cancer when: v. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is decreased or the same when compared to the reference standard, when the reference standard is from a granulocyte unsuitable for treating cancer; or vi. the measured expression level of ANXA1 and/or PPP3CB is increased or the same when compared to the reference standard, when the reference standard is from a granulocyte unsuitable for treating cancer; or vii. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is decreased when compared to reference standard, when the reference standard is from a granulocyte suitable for treating cancer; or viii. the measured expression level of ANXA1 and/or PPP3CB is increased when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer.

4. A method for selecting whether or not a subject is suitable for treatment with a granulocyte or a stem cell for treating cancer, the method comprising: a. comparing a measured expression level of one or more genes by a granulocyte comprised in a sample obtainable from the subject, wherein the one or more genes are associated with suitability for treating cancer and are selected from: GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PPP3CB, ANXA1, PERM, PLEC, ACSL1, RAC1, and PSMB2with the expression level of the same one or more genes in a reference standard; and b. identifying whether or not the subject is suitable for treatment with a granulocyte or a stem cell for treating cancer based on the comparison.

5. A method for determining a subject’s risk for developing cancer, the method comprising: a. comparing a measured expression level of one or more genes by a granulocyte comprised in a sample obtainable from the subject, wherein the one or more genes are associated with suitability for treating cancer and are selected from: GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PPP3CB, ANXA1, PERM, PLEC, ACSL1, RAC1, and PSMB2with the expression level of the same one or more genes in a reference standard; and b. determining the subject’s risk for developing cancer based on the comparison.

6. The method according to claim 4 or 5, wherein step b. comprises: identifying the subject as suitable for treatment with a granulocyte or a stem cell for treating cancer or determining that the subject is at risk of developing cancer when: i. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMKATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is decreased or the same when compared to the reference standard, when the reference standard is from a granulocyte unsuitable for treating cancer; or ii. the measured expression level of ANXA1 and/or PPP3CB is increased or the same when compared to the reference standard, when the reference standard is from a granulocyte unsuitable for treating cancer; or iii. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is decreased when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer; or iv. the measured expression level of ANXA1 and/or PPP3CB is increased when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer; or identifying the subject as unsuitable for treatment with a granulocyte or a stem cell for treating cancer when or determining that the subject is not at risk of developing cancer when: v. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is increased when compared to the reference standard when the reference standard is from a granulocyte unsuitable for treating cancer; or vi. the measured expression level of ANXA1 and/or PPP3CB is decreased when compared to the reference standard, when the reference standard is from a granulocyte unsuitable for treating cancer; or vii. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is increased or the same when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer; or viii. the measured expression level of ANXA1 and/or PPP3CB is decreased or the same when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer.

7. The method according any one of the preceding claims, wherein the method further comprises measuring the expression of the one or more genes.

8. The method according to any one of the preceding claims, wherein the granulocyte is a neutrophil.

9. The method according to any one of the preceding claims, further comprising measuring the expression level of one or more gene selected from: S100A9 and S100A8.

10. The method according to any one of the preceding claims, wherein the one or more genes associated with suitability for treating cancer are one or more genes associated with: a. killing cancer cells and are selected from: GM2A, CTSG, CAP37, CYBB, GZMK, ATM, PERM, ACSL1, ATG7, SYK, DOCK8, RAC1, and PSMB2; and/or b. locating and/or binding to cancer cells and are selected from: ANXA1, ITGB1, COMP, SLC2A1 and PLEC; and/or c. recruitment of immune mediators and are selected from: BCAP31, TAPBP, IKBKB, and PPP3CB.

11. The method according to any one of the preceding claims, wherein the expression level is measured by proteomic techniques.

12. The method according to any one of the preceding claims, wherein the expression level is measured by transcriptomic techniques.

13. The method according to any one of claims 1-3 or 7-12 further comprising selecting a granulocyte when the granulocyte has been determined to be suitable for treating cancer or selecting a granulocyte from a sample obtainable from a donor when the donor has been identified as a donor that produces granulocytes for treating cancer, preferably wherein the selecting comprises isolating the granulocyte.

14. An in vitro method for obtaining a granulocyte for treating cancer, said method comprising obtaining a granulocyte from a sample obtainable from a donor wherein said donor produces granulocytes comprising: a. increased expression of one or more of ITGB1, CYBB, SYK, DOCK8, COMP, ATG7, SLC2A1, GZMK, CTSG, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, GM2A, CAP37, and PSMB2 when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer; and/or b. decreased expression of ANXA1 and/or PPP3CB when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer.

15. An in vitro method for obtaining a stem cell for treating cancer, said method comprising obtaining a stem cell from a sample obtainable from a donor wherein said donor produces granulocytes comprising: a. increased expression of one or more of ITGB1, CYBB, SYK, DOCK8, COMP, ATG7, SLC2A1, GZMK, CTSG, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, GM2A, CAP37, and PSMB2 when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer; and/or b. decreased expression of ANXA1 and/or PPP3CB when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer.

16. A method for preparing a stem cell suitable for treating cancer, the method comprising: a. identifying a donor that produces granulocytes suitable for treating cancer according to the method of any one of claims 2-3 or 7-13; and b. obtaining the stem cell from a sample obtainable from said donor.

17. A method for producing a stem cell for treating cancer, the method comprising: a. providing a stem cell obtainable from a sample from a donor wherein said donor produces granulocytes comprising: i. increased expression of one or more of ITGB1, CYBB, SYK, DOCK8, COMP, ATG7, SLC2A1, GZMK, CTSG, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, GM2A, CAP37, and PSMB2 when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer; and/or ii. decreased expression of ANXA1 and/or PPP3CB when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer ; and b. differentiating the stem cell into a different stem cell (preferably a precursor cell); and c. optionally isolating the different stem cell (preferably the precursor cell).

18. The method according to any one of claims 15-17 wherein the sample comprises a somatic cell and obtaining the stem cell from the sample comprises reprograming the somatic cell into a stem cell.

19. A method for isolating a granulocyte or stem cell for treating cancer, the method comprising: a. contacting a sample of granulocytes or a sample of stem cells with a binding means, wherein the binding means binds to one or more polypeptides selected from GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PPP3CB, ANXA1, PERM, PLEC, ACSL1, RAC1, and PSMB2; and b. isolating the granulocyte or stem cell, respectively, based on the presence or absence of binding between the binding means and the one or more polypeptides.

20. A method for producing an engineered granulocyte or stem cell for treating cancer, the method comprising: a. providing a granulocyte or stem cell, respectively; and b. engineering the granulocyte or stem cell, respectively, to: i. increase expression of one or more genes selected from: GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2; and/or ii. decrease expression of ANXA1 and/or PPP3CB; thereby producing the engineered granulocyte or stem cell, respectively, wherein the engineered granulocyte or stem cell, respectively, is suitable for treating cancer.

21. A stem cell for treating cancer obtainable by the method according to any one of claims 15-20.

22. A stem cell which is capable of differentiating into a granulocyte for treating cancer, wherein the granulocyte comprises: a. increased expression of one or more of ITGB1, CYBB, SYK, DOCK8, COMP, ATG7, SLC2A1, GZMK, CTSG, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, GM2A, CAP37, and PSMB2 when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer; and/or b. decreased expression of ANXA1 and/or PPP3CB when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer.

23. The stem cell according to claim 21 or 22, wherein the stem cell is an induced pluripotent stem cell, or wherein the stem cell is a haematopoietic stem cell, a common myeloid progenitor cell, a myeloblast, a N. promyelocyte, a N. myelocyte, a N. metamyelocyte, a N. band, or combinations thereof; preferably wherein the stem cell is a haematopoietic stem cell.

24. A method for producing a granulocyte for treating cancer, the method comprising: a. providing a cell; and b. converting the cell into a granulocyte wherein: i. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is increased in the granulocyte when compared to a reference standard when the reference standard is from a granulocyte unsuitable for treating cancer; or ii. the measured expression level of ANXA1 and/or PPP3CB is decreased in the granucloyte when compared to the reference standard, when the reference standard is from a granulocyte unsuitable for treating cancer; or iii. the measured expression level of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 is increased or the same when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer; or iv. the measured expression level of ANXA1 and/or PPP3CB is decreased or the same when compared to the reference standard, when the reference standard is from a granulocyte suitable for treating cancer; and optionally isolating the granulocyte.

25. The method according to claim 24 wherein the cell is a stem cell according to any one of claims 21-23.

26. The method according to claim 25 wherein converting the stem cell into a granulocyte comprises differentiating the stem cell into a granulocyte.

27. The method according to claim 24 wherein the cell is a somatic/differentiated cell, optionally from a donor who produces granulocytes suitable for treating cancer as determined according to any one of claims 2-3 or 7-13.

28. The method according to claim 27 wherein converting the somatic/differentiated cell into a granulocyte comprises transdifferentiating the somatic/differentiated cell into a granulocyte.

29. A granulocyte (e.g. obtainable by the method according to any one of claims 13, 19-20 or 24-28), wherein the granulocyte comprises: a. increased expression of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer; and/or b. decreased expression of ANXA1 and/or PPP3CB when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer.

30. A composition for treating cancer (e.g. obtainable by the method according to any one of claims 13, 19-20 or 24-28), the composition comprising granulocytes: wherein at least 90% of the granulocytes comprised in the composition have: a. increased expression of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer; and/or b. decreased expression of ANXA1 and/or PPP3CB when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer.

31. The composition according to claim 30, wherein at least 95%, 99% or 100% of the granulocytes comprised in the composition have: a. increased expression of one or more of GM2A, CTSG, CAP37, ITGB1, CYBB, SYK, DOCK8,COMP, ATG7, SLC2A1, GZMK, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, and PSMB2 when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer; and/or b. decreased expression of ANXA1 and/or PPP3CB when compared to a reference standard, wherein the reference standard is from a granulocyte unsuitable for treating cancer.

32. A pharmaceutical composition comprising: a. the granulocyte according to claim 29, the stem cell according to any one of claims 21-23 , or the composition according to claim 30 or 31; and b. a pharmaceutically acceptable carrier, excipient, adjuvant, and/or salt.

33. The pharmaceutical composition according to claim 32, further comprising TNF-alpha.

34. The pharmaceutical composition according to any one of claims 32-33, further comprising a granulocyte-macrophage colony-stimulating factor (GM-CSF), a granulocyte colony-stimulating factor (G-CSF), a growth hormone, and serotonin, vitamin C, vitamin D, glutamine (Gln), arachidonic acid, AGE-albumin, an interleukin, TNF-alpha, Flt-3 ligand, thrombopoietin, foetal bovine serum (FBS), retinoic acid, lipopolysaccharide (LPS), IFN-gamma, IFN-beta, or combinations thereof.

35. The pharmaceutical composition according to any one of claims 32–34, further comprising a granulocyte-macrophage colony-stimulating factor (GM-CSF) and IFN-gamma.

36. A kit comprising: a. the granulocyte according to claim 29, the stem cell according to any one of claims 21–23, the composition according to claim 30 or 31, or the pharmaceutical composition according to any one of claims 32–35; and b. instructions for use of the same in medicine.

37. A granulocyte according to claim 29, stem cell according to any one of claims 21–23, composition according to claim 30 or 31, pharmaceutical composition according to any one of claims 32–35, or kit according to claim 36 for use in treating cancer.

38. Use of the granulocyte according to claim 29, the stem cell according to any one of claims 21–23, the composition according to claim 30 or 31, the pharmaceutical composition according to any one of claims 32–35, or the kit according to claim 36 in the manufacture of a medicament for treating cancer.

39. A method for treating cancer comprising: administering to a subject in need thereof the granulocyte according to claim 29, the stem cell according to any one of claims 21-23, the composition according to claim 30 or 31, the pharmaceutical composition according to any one of claims 32–35, or the kit according to claim 36.

40. The granulocyte for use, stem cell for use, composition for use, pharmaceutical composition for use, or kit for use according to claim 37, the use according to claim 38 or the method according to claim 39, wherein the cancer is one or more of: pancreatic cancer, liver cancer, oesophageal cancer, stomach cancer, cervical cancer, ovarian cancer, lung cancer, bladder cancer, kidney cancer, brain cancer, prostate cancer, myeloma cancer, non-Hodgkin’s lymphoma (NHL), larynx cancer, uterine cancer, or breast cancer; preferably wherein the cancer is pancreatic cancer.

41. A cell bank comprising the granulocyte according to claim 29, the stem cell according to any one of claims 21–23, the composition according to claim 30 or 31, or the pharmaceutical composition according to any one of claims 32–35.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0452] Embodiments of the invention will now be described, by way of example only, with reference to the following Figures and Examples.

[0453] FIG. 1 shows the distribution of different types of neutrophils in the general population. Defective neutrophils are characterised by an anti-inflammatory and proangiogenic phenotype whereas healthy neutrophils are characterised by a proinflammatory and antiangiogenic phenotype. Finally, exceptional neutrophils are present in a proportion of the general population and exhibit the extreme of all qualities found in healthy neutrophils.

[0454] FIG. 2 shows significantly (***P < 0.001, **P < 0.01, *P < 0.05) upregulated expression of ITGB1, SYK, DOCK8 and CYBB in high CKA neutrophils (>80% CKA) compared with low CKA control neutrophils. Data are mean (n = 3 donor samples in duplicate) ± standard error of mean compared by two-way ANOVA.

[0455] FIG. 3 shows significantly (**P < 0.01, *P < 0.05) upregulated expression of PLEC and COMP in high CKA neutrophils (>80% CKA) compared with low CKA control neutrophils. Data are mean (n = 3 donor samples in duplicate) ± standard error of mean compared by two-way ANOVA.

[0456] FIG. 4 shows significantly (**P < 0.01, *P < 0.05) upregulated expression of ATG7, SLC2A1, S100A9, ACSL1, CTSG, PSMB2, ATM and S100A8 in high CKA neutrophils (>80% CKA) compared with low CKA control neutrophils. Data are mean (n = 3 donor samples in duplicate) ± standard error of mean compared by two-way ANOVA.

[0457] FIG. 5 shows significantly (**P < 0.01, *P < 0.05) downregulated expression of ANXA1 in high CKA neutrophils (>80% CKA) compared with low CKA control neutrophils. Data are mean (n = 3 donor samples in duplicate) ± standard error of mean compared by two-way ANOVA.

[0458] FIG. 6 shows significantly (**P < 0.01, *P < 0.05) upregulated expression of BCAP31 and TAPBP in high CKA neutrophils (>80% CKA) compared with low CKA control neutrophils. Data are mean (n = 3 donor samples in duplicate) ± standard error of mean compared by two-way ANOVA.

SEQUENCE LISTING

[0459] TABLE-US-00003 Gene Sequences SEQ ID NO. GENE Accession No. Ensembl Release No. 1 CTSG ENSG00000100448 97 2 CAP37 ENSG00000172232 97 3 ITGB1 ENSG00000150093 97 4 CYBB ENSG00000165168 97 5 SYK ENSG00000165025 97 6 DOCK8 ENSG00000107099 97 7 COMP ENSG00000105664 97 8 ATG7 ENSG00000197548 97 9 SLC2A1 ENSG00000117394 97 10 GZMK ENSG00000113088 97 11 S100A9 ENSG00000163220 97 12 S100A8 ENSG00000143546 97 13 ATM ENSG00000149311 97 14 IKBKB ENSG00000104365 97 15 BCAP31 ENSG00000185825 97 16 TAPBP ENSG00000231925 97 17 PPP3CB ENSG00000107758 97 18 ANXA1 ENSG00000135046 97 19 PERM ENSG00000005381 97 20 PLEC ENSG00000178209 97 21 ACSL1 ENSG00000151726 97 22 RAC1 ENSG00000136238 97 23 PSMB2 ENSG00000126067 97

POLYPEPTIDE SEQUENCES

[0460] TABLE-US-00004 SEQ ID NO. POLYPEPTIDE ISOFORM UniProt ID UniProt Version Number SEQUENCE 25 CTSG 1 P08311 Entry version 191 (18 Sep. 2019) Sequence version 2 (01 Jan. 1990) MQPLLLLLAF IIGGRESRPH QSPAGQSRCG TAAHCWGSNI RRENTQQHIT NQRTIQNDIM NRNVNPVALP LCTVAGWGRV EVQLRVQRDR PRRQICVGDR SGGPLLCNNV AHGIVSYGKS TMRSFKLLDQ LLPTGAEAGE SRPYMAYLQI GFLVREDFVL NVTLGAHNIQ ARRAIRHPQY LLQLSRRVRR RAQEGLRPGT SMRRGTDTLR QCLRIFGSYD RERKAAFKGD SGVPPEVFTR VSSFLPWIRT METPL 26 CAP37 1 P20160 Entry version 191 (18 Sep. 2019) Sequence version 3 (01 Oct. 1993) MTRLTVLALL SSPLLDIVGG LASIQNQGRH FVMTAASCFQ LGAYDLRRRE SMSENGYDPQ LDREANLTSS ATVEAGTRCQ GRLSRFPRFV RPNNVCTGVL GGTPLVCEGL PCGRGPDFFT GVLNNPGPGP AGLLASSRAG RKARPRQFPF FCGGALIHAR SQNPGVSTVV RQSRQTFSIS QNLNDLMLLQ VTILPLPLQN VAGWGSQRSG NVTVTPEDQC TRRGGICNGD AHGVASFSLG RVALFRDWID A 27 ITGB1 1 P05556 Entry version 242 (18 Sep. 2019) Sequence version 2 (16 Dec. 2008) MNLQPIFWIG QTDENRCLKA AGPNCGWCTN SARCDDLEAL ENPRGSKDIK GTAEKLKPED LRLRSGEPQT YPIDLYYLMD NVKSLGTDLM RIGFGSFVEK LISSVCCVFA NAKSCGECIQ STFLQEGMPT KKKGCPPDDI KNKNVTNRSK ITQIQPQQLV FTLKFKRAED LSYSMKDDLE NEMRRITSDF TVMPYISTTP 27 ITGB1 1 P05556 Entry version 242 (18 Sep. 2019) Sequence version 2 (16 Dec. 2008) MNLQPIFWIG QTDENRCLKA AGPNCGWCTN SARCDDLEAL ENPRGSKDIK GTAEKLKPED LRLRSGEPQT YPIDLYYLMD NVKSLGTDLM RIGFGSFVEK LISSVCCVFA NAKSCGECIQ STFLQEGMPT KKKGCPPDDI KNKNVTNRSK ITQIQPQQLV FTLKFKRAED LSYSMKDDLE NEMRRITSDF TVMPYISTTP AKLRNPCTSE NVLSLTNKGE ISGNLDSPEG CGSLIGWRNV GFHFAGDGKL CHLENNMYTM HLVQKLSENN FQPVYKELKN SANSSNVIQL EVILENGKLS CKNGVNGTGE GDEVQFEISI DSFKIRPLGF ICECECQSEG NGTFECGACR ECSTDEVNSE SSEICSNNGE RDNTNEIYSG DRSNGLICGG CNPNYTGSAC ASNGQICNGR TDPKFQGQTC AEHKECVQCR CTQECSYFNI QPVQPDPVSH FYFTYSVNGN PECPTGPDII VLIGLALLLI REFAKFEKEK PIYKSAVTTV QNCTSPFSYK VFNELVGKQR GFDAIMQVAV TRLLVFSTDA GGIVLPNDGQ SHYYDYPSIA IQTIFAVTEE LIPKSAVGTL IIDAYNSLSS EGVTISYKSY NGRKCSNISI TSNKCPKKDS TEEVEVILQY IPESPKCHEG CNEGRVGRHC DMDAYCRKEN CVCGQCVCRK KFCECDNFNC NGVCKCRVCE DCSLDTSTCE GICECGVCKC EMCQTCLGVC AFNKGEKKDT TKVESRDKLP CKEKDVDDCW NEVMVHVVEN PIVAGVVAGI WKLLMIIHDR MNAKWDTGEN VNPKYEGK 28 ITGB1 2 P055562 Entry version 242 (18 Sep. 2019) Sequence version 2 (16 Dec. 2008) MNLQPIFWIG QTDENRCLKA AGPNCGWCTN SARCDDLEAL ENPRGSKDIK GTAEKLKPED LRLRSGEPQT YPIDLYYLMD NVKSLGTDLM RIGFGSFVEK AKLRNPCTSE NVLSLTNKGE ISGNLDSPEG CGSLIGWRNV GFHFAGDGKL CHLENNMYTM HLVQKLSENN FQPVYKELKN SANSSNVIQL EVILENGKLS CKNGVNGTGE GDEVQFEISI DSFKIRPLGF ICECECQSEG NGTFECGACR ECSTDEVNSE SSEICSNNGE RDNTNEIYSG DRSNGLICGG LISSVCCVFA NAKSCGECIQ STFLQEGMPT KKKGCPPDDI KNKNVTNRSK ITQIQPQQLV FTLKFKRAED LSYSMKDDLE NEMRRITSDF TVMPYISTTP QNCTSPFSYK VFNELVGKQR GFDAIMQVAV TRLLVFSTDA GGIVLPNDGQ SHYYDYPSIA IQTIFAVTEE LIPKSAVGTL IIDAYNSLSS EGVTISYKSY NGRKCSNISI TSNKCPKKDS TEEVEVILQY IPESPKCHEG CNEGRVGRHC DMDAYCRKEN CVCGQCVCRK KFCECDNFNC NGVCKCRVCE CNPNYTGSAC ASNGQICNGR TDPKFQGQTC AEHKECVQCR CTQECSYFNI QPVQPDPVSH FYFTYSVNGN PECPTGPDII VLIGLALLLI REFAKFEKEK KTSKKQSGL DCSLDTSTCE GICECGVCKC EMCQTCLGVC AFNKGEKKDT TKVESRDKLP CKEKDVDDCW NEVMVHVVEN PIVAGVVAGI WKLLMIIHDR MNAKWDTVSY 29 ITGB1 3 P055563 Entry version 242 (18 Sep. 2019) Sequence version 2 (16 Dec. 2008) MNLQPIFWIG QTDENRCLKA AGPNCGWCTN SARCDDLEAL ENPRGSKDIK GTAEKLKPED LRLRSGEPQT YPIDLYYLMD NVKSLGTDLM RIGFGSFVEK AKLRNPCTSE NVLSLTNKGE ISGNLDSPEG CGSLIGWRNV GFHFAGDGKL CHLENNMYTM HLVQKLSENN FQPVYKELKN SANSSNVIQL EVILENGKLS CKNGVNGTGE GDEVQFEISI DSFKIRPLGF ICECECQSEG NGTFECGACR ECSTDEVNSE SSEICSNNGE RDNTNEIYSG DRSNGLICGG CNPNYTGSAC ASNGQICNGR TDPKFQGQTC AEHKECVQCR CTQECSYFNI QPVQPDPVSH FYFTYSVNGN PECPTGPDII VLIGLALLLI REFAKFEKEK VAQPGVQWCD FQQFSCLSLP FIRVP LISSVCCVFA NAKSCGECIQ STFLQEGMPT KKKGCPPDDI KNKNVTNRSK ITQIQPQQLV FTLKFKRAED LSYSMKDDLE NEMRRITSDF TVMPYISTTP QNCTSPFSYK VFNELVGKQR GFDAIMQVAV TRLLVFSTDA GGIVLPNDGQ SHYYDYPSIA IQTIFAVTEE LIPKSAVGTL IIDAYNSLSS EGVTISYKSY NGRKCSNISI TSNKCPKKDS TEEVEVILQY IPESPKCHEG CNEGRVGRHC DMDAYCRKEN CVCGQCVCRK KFCECDNFNC NGVCKCRVCE DCSLDTSTCE GICECGVCKC EMCQTCLGVC AFNKGEKKDT TKVESRDKLP CKEKDVDDCW NEVMVHVVEN PIVAGVVAGI WKLLMIIHDR MNAKWDTSLS ISSLQPLTSR STWDYRVKIL 30 ITGB1 4 P055564 Entry version 242 (18 Sep. 2019) Sequence version 2 (16 Dec. 2008) MNLQPIFWIG QTDENRCLKA AGPNCGWCTN SARCDDLEAL ENPRGSKDIK GTAEKLKPED LISSVCCVFA NAKSCGECIQ STFLQEGMPT KKKGCPPDDI KNKNVTNRSK ITQIQPQQLV LRLRSGEPQT YPIDLYYLMD NVKSLGTDLM RIGFGSFVEK AKLRNPCTSE NVLSLTNKGE ISGNLDSPEG CGSLIGWRNV GFHFAGDGKL CHLENNMYTM HLVQKLSENN FQPVYKELKN SANSSNVIQL EVILENGKLS CKNGVNGTGE GDEVQFEISI DSFKIRPLGF ICECECQSEG NGTFECGACR ECSTDEVNSE SSEICSNNGE RDNTNEIYSG DRSNGLICGG CNPNYTGSAC ASNGQICNGR TDPKFQGQTC AEHKECVQCR CTQECSYFNI QPVQPDPVSH FYFTYSVNGN PECPTGPDII VLIGLALLLI REFAKFEKEK QWCDISSLQP LSLPSTWDYR FTLKFKRAED LSYSMKDDLE NEMRRITSDF TVMPYISTTP QNCTSPFSYK VFNELVGKQR GFDAIMQVAV TRLLVFSTDA GGIVLPNDGQ SHYYDYPSIA IQTIFAVTEE LIPKSAVGTL IIDAYNSLSS EGVTISYKSY NGRKCSNISI TSNKCPKKDS TEEVEVILQY IPESPKCHEG CNEGRVGRHC DMDAYCRKEN CVCGQCVCRK KFCECDNFNC NGVCKCRVCE DCSLDTSTCE GICECGVCKC EMCQTCLGVC AFNKGEKKDT TKVESRDKLP CKEKDVDDCW NEVMVHVVEN PIVAGVVAGI WKLLMIIHDR MNAKWDTPGV LTSRFQQFSC VKILFIRVP 31 ITGB1 5 P055565 Entry version 242 (18 Sep. 2019) Sequence version 2 (16 Dec. 2008) MNLQPIFWIG QTDENRCLKA AGPNCGWCTN SARCDDLEAL ENPRGSKDIK GTAEKLKPED LRLRSGEPQT YPIDLYYLMD NVKSLGTDLM RIGFGSFVEK AKLRNPCTSE NVLSLTNKGE ISGNLDSPEG CGSLIGWRNV GFHFAGDGKL CHLENNMYTM HLVQKLSENN FQPVYKELKN SANSSNVIQL EVILENGKLS CKNGVNGTGE GDEVQFEISI DSFKIRPLGF ICECECQSEG NGTFECGACR LISSVCCVFA NAKSCGECIQ STFLQEGMPT KKKGCPPDDI KNKNVTNRSK ITQIQPQQLV FTLKFKRAED LSYSMKDDLE NEMRRITSDF TVMPYISTTP QNCTSPFSYK VFNELVGKQR GFDAIMQVAV TRLLVFSTDA GGIVLPNDGQ SHYYDYPSIA IQTIFAVTEE LIPKSAVGTL IIDAYNSLSS EGVTISYKSY NGRKCSNISI TSNKCPKKDS TEEVEVILQY IPESPKCHEG CNEGRVGRHC ECSTDEVNSE SSEICSNNGE RDNTNEIYSG DRSNGLICGG CNPNYTGSAC ASNGQICNGR TDPKFQGQTC AEHKECVQCR CTQECSYFNI QPVQPDPVSH FYFTYSVNGN PECPTGPDII VLIGLALLLI REFAKFEKEK PIYKSPINNF L DMDAYCRKEN CVCGQCVCRK KFCECDNFNC NGVCKCRVCE DCSLDTSTCE GICECGVCKC EMCQTCLGVC AFNKGEKKDT TKVESRDKLP CKEKDVDDCW NEVMVHVVEN PIVAGVVAGI WKLLMIIHDR MNAKWDTQEN KNPNYGRKAG 32 CYBB 1 P04839 Entry version 213 (18 Sep. 2019) Sequence version 2 (23 Jan. 2007) MGNWAVNEGL LNVFLFVWYY YTRKLLGSAL NFNCMLILLP GSSACCSTRV HKMVAWMIAL FNVEWCVNAR LSELGDRQNE KNPEGGLYLA VITLCLILII YFEVFWYTHH IHGAERIVRG ITVCEQKISE QFAGNPPMTW LCERLVRFWR VTHPFKTIEL VGQYIFVKCP TLTSAPEEDF WTEGLFNACG KLPKIAVDGP YEVVMLVGAG KSVWYKYCNN FYWLCRDTHA LESQMQERNN TGWDESQANH VITGLKQKTL KTIASQHPNT ALAETLSKQS VHFIFNKENF SIFVILVWLG RVYDIPPKFF ALARAPAACL VCRNLLSFLR RRQLDRNLTF HSAIHTIAHL VNNSDPYSVA SYLNFARKRI VTLLAGITGV TSSTKTIRRS LFVIFFIGLA QTAESLAVHN WGKIKECPIP KWIVGPMFLY SQQKWITKV QMKKKGFKME KVSKLEWHPF FSIHIRIVGD CDKQEFQDAW FGTASEDVFS IGVTPFASIL ATNLKLKKIY FEWFADLLQL AGFLSYNIYL FAVHHDEEKD YGRPNWDNEF RIGVFLCGPE ISNSESGPRG 33 SYK 1 P43405 Entry version 224 (18 Sep. 2019) Sequence version 1 (01 Nov. 1995) MASSGMADSA TREEAEDYLV LRQSRNYLGG AHHYTIEREL THASPADLCH CLLKKPFNRP EDLKENLIRE QALEQAIISQ TAHEKMPWFH IVLIGSKTNG GSYALCLLHE DKTGKLSIPE VEHYSYKADG NHLPFFFGNI QGGMSDGLYL FALSVAHGRK NGTYAIAGGR YHSQESDGLV QGVQPKTGPF YVKQTWNLQG KPQLEKLIAT GKISREESEQ KFLIRARDNN GKVLHYRIDK GKKFDTLWQL LLRVLTVPCQ KIGTQGNVNF PATWSAGGII PGHRKSSPAQ NPYEPELAPW LPMDTEVYES KEVYLDRKLL NFGTVKKGYY VKILKNEAND ANVMQQLDNP AESWMLVMEM QQNRHVKDKN GMKYLEESNF LLVTQHYAKI ADENYYKAQT PECINYYKFS LMWEAFSYGQ VTAMLEKGER MYDLMNLCWT AVELRLRNYY GGRPQLPGSH SRIKSYSFPK GNRQESTVSF AADKGPQREA PYADPEEIRP TLEDKELGSG QMKKVVKTVA PALKDELLAE YIVRMIGICE AELGPLNKYL IIELVHQVSM VHRDLAARNV SDFGLSKALR HGKWPVKWYA SKSDVWSFGV KPYRGMKGSE MGCPAGCPRE YDVENRPGFA YDVVN 34 SYK 2 P434052 Entry version 224 (18 Sep. 2019) Sequence version 1 (01 Nov. 1995) MASSGMADSA TREEAEDYLV LRQSRNYLGG AHHYTIEREL THASPADLCH CLLKKPFNRP EDLKENLIRE QALEQAIISQ TAHEKMPWFH IVLIGSKTNG GSYALCLLHE DKTGKLSIPE VEHYSYKADG KIGTQGNVNF PASSPAQGNR EPELAPWAAD DTEVYESPYA YLDRKLLTLE TVKKGYYQMK LKNEANDPAL MQQLDNPYIV WMLVMEMAEL RHVKDKNIIE YLEESNFVHR TQHYAKISDF NYYKAQTHGK INYYKFSSKS EAFSYGQKPY MLEKGERMGC LMNLCWTYDV LRLRNYYYDV NHLPFFFGNI QGGMSDGLYL FALSVAHGRK NGTYAIAGGR YHSQESDGLV QGVQPKTGPF YVKQTWNLQG KPQLEKLIAT GKISREESEQ KFLIRARDNN GKVLHYRIDK GKKFDTLWQL LLRVLTVPCQ GGRPQLPGSH QESTVSFNPY KGPQREALPM DPEEIRPKEV DKELGSGNFG KVVKTVAVKI KDELLAEANV RMIGICEAES GPLNKYLQQN LVHQVSMGMK DLAARNVLLV GLSKALRADE WPVKWYAPEC DVWSFGVLMW RGMKGSEVTA PAGCPREMYD ENRPGFAAVE VN 35 DOCK8 1 Q8NF50 Entry version 160 (18 Sep. 2019) Sequence version 3 (21 Aug. 2007) MATLPSAERR SAEIRKQFTL SISTSGFPSL PVDFEGLLMT QELGDFTDDD RTLQPSLPEE CVQTYIREWL EICGFKKTGS AFALKINRYS PPNLGQYHRQ QLPQFYDPVE HLNSLDVQLA LDVVFTPKEC GVELDPHVRD IVNRKNQGSP RKDFHKTLPK QTFESETLEC HLNVLCDVSG LRSLQPDKRL DFEKQNEEAR LYPSVDEEDA KEHLGNRILV IEPLFASIAL ENFHCDLNSD PSVAASSQAR SDIYLVVKIE CAEPYTVIKE EKLKLQAESF FAWAPISLSS VTDVDSVVGR QSRRLSERAL FKTSTLSVSS DEDLFKFLAD VKSIPGLLRL CCLTPEMLPV HKEILEFPTR NLLYVYPQRL NITIKIQFMC IFGKSSGPEF HNKSPDFYEE VNHHLLFTFY SVETLLGYSW TGSYCLPVAL SAEKVPLQNP VFNIEVQAVS KFFTLCHSLE DQKISEMALE NSSRLEPLVL QLSVQPMVIA FESVVAIANS QHGRNCLLAS VQRDVPKSGA HTYGRTSAAA MSSSNPDLAG NIMSSKIADR GSSDAPSSPA HEELALQMW KYAWFFFELL MDKRDSFRRT TTIVNVVTSE ENEQAEKMNI SLMDRGFVFN AKLSNLPTLI CSHEHYLNLN TSPCPSISSQ QKIASMFDLT GLLFTELAAA VQRKAVSAIH RCVKPEVKVK IILDALPQLC RTSGSDEEQE LAIAGNNFNL PYKQYNMLNA LWIMKNADQS STQLNRILDL KGKQSSDKVS SEPAAQAGPR KGPVTACDFD ENLLQQVSAE RTNRQAELFA VEIRPVPECP KLLTLKFEIE YDVKERKKIS QFKGFLRAHT SAVFSVTYPS KVLQQGEIGD SDGGKSKEKI CQRLGKYRMP FFNVSTLERE SSVGERRTLA SLEENGVGSN FFKQEGDRLS YKRSSSLQRR EISTAPEIIN KPFPENRTRP EVYVPHTVYR NFVNKLASAR GEDASNAMPV LQEVYTAVTY VKIKLPAKLT HISCQQKQGA LPILLNERLQ EKLPPNYSMH PIKWAEGHKG SVHTQDNHLE SQVTFPIRVL HELKLSIICL FLHLVLDKLF GQTANFSQFA LHNSKDLSKD YVHYVFRLPE PTALLDPRSY VSSKLLQARV THSAADEEVK NCSRMSYYCS APRPASKKHF STGMVRETVF VKSMAQHVHN RFSDRFMDDI IAALLVKPQK SLAFFLYDLL LIRHYCSQLS SMRLEFLRIL LFFMNADTAP NSSSCSSFQD SEYRQQHFLT LDAEGEGISK SLLSSHDLDP IAALYLPLVG DFTVADTRRY GAGAINQNVA KTSGIVLSSL DTTRNLMICF LIRKWIADLP LFICVLCFEY TQVLQKSRDV KARLEEALLR EQTHWRQANE QEALISGNLA QENIIQASSA VLRVLVNSLN CFATLRALIA VEQCFDLCHQ VTRSQACATL TSNFARVKMQ RAPDFNEEHL SEEDTAMQMT CNLNSILYDT EMLMDLMYRI RLTWLQNMAE AAMCLVHAAA DHSYLPVGSV EESVVSEDTL QYFTESGLVG TGGLYETVNE AHREFRKLTL SIVNKDHKRM GSKFGDLDEQ KLPEISHRLE FVEVIKDSTP AYIQITFVEP YFDEYEMKDR VTYFEKNFNL LEGRPRGELH TMHAFPYIKT VLTPIEVAIE VAINQEPPDA VGATVNQGPL PADPKLYRHH IMRCGEAVEK EYQQELKKNY IERKIPELYK DSFHRSSFRK GEGARGEMMR RRAPGNDRFP GLNENLRWKK KLDKTKAELD TEAHLIILDM LDCKDSLLGG CDQSTTYLTH KFGDLLFEEE VLHHCSSSMD YLLMRFSFGA VTMSLASLVG RRSLRTILAY PFPTQVEELL VKMREFQEDP AKSYQASPDL KHTKKKCYTE LVAEYLSMLE SFQNISSNVL SPDEDGVCAG LLEQAAELFS VYKLVIPILE THSKLQRAFD FGTYFRVGFF EFVYKEPAIT AFYGQCFGAE VDKTKLDPNK RRFMYTTPFT EQYRRNTVLT RISVIQKEEF DMKKKTLQLA KMLQMVLQGS EVAQVFLAEI NKLRLCFKEF NKRLITADQR NKLKENLRPM PIFRVESQKR CETQLSQGS 36 DOCK8 2 Q8NF502 Entry version 160 (18 Sep. 2019) Sequence version 3 (21 Aug. 2007) MATLPSAERR SAEIRKQFTL SISTSGFPSL PVDFEGLLMT QELGDFTDDD RTLQPSLPEE CVQTYIREWL EICGFKKTGS QTFESETLEC HLNVLCDVSG LRSLQPDKRL DFEKQNEEAR LYPSVDEEDA KEHLGNRILV IEPLFASIAL ENFHCDLNSD PSVAASSQAR SDIYLVVKIE CAEPYTVIKE EKLKLQAESF FAWAPISLSS VTDVDSVVGR AFALKINRYS PPNLGQYHRQ QLPQFYDPVE HLNSLDVQLA LDVVFTPKEC GVELDPHVRD IVNRKNQGSP RKDFHKTLPK SEPAAQAGPR KGPVTACDFD ENLLQQVSAE RTNRQAELFA VEIRPVPECP KLLTLKFEIE YDVKERKKIS QFKGFLRAHT SAVFSVTYPS KVLQQGEIGD SDGGKSKEKI CQRLGKYRMP FFNVSTLERE SSVGERRTLA QSRRLSERAL FKTSTLSVSS DEDLFKFLAD VKSIPGLLRL CCLTPEMLPV HKEILEFPTR NLLYVYPQRL NITIKIQFMC IFGKSSGPEF HNKSPDFYEE VNHHLLFTFY SVETLLGYSW TGSYCLPVAL SAEKVPLQNP VFNIEVQAVS KFFTLCHSLE DQKISEMALE NSSRLEPLVL QLSVQPMVIA FESVVAIANS QHGRNCLLAS VQRDVPKSGA HTYGRTSAAA MSSSNPDLAG NIMSSKHFHE GMVRETVFKY SMAQHVHNMD SDRFMDDITT ALLVKPQKEN AFFLYDLLSL RHYCSQLSAK RLEFLRILCS FMNADTAPTS SSCSSFQDQK YRQQHFLTGL AEGEGISKVQ LSSHDLDPRC ALYLPLVGII TVADTRRYRT GAINQNVALA SGIVLSSLPY TRNLMICFLW RKWIADLPST ICVLCFEYKG VLQKSRDVKA GARGEMMRRR NENLRWKKEQ DKTKAELDQE AHLIILDMQE CKDSLLGGVL QSTTYLTHCF GDLLFEEEVE HHCSSSMDVT LMRFSFGATS MSLASLVGRA SLRTILAYSE PTQVEELLCN MREFQEDPEM SYQASPDLRL TKKKCYTEAA SLEENGVGSN FFKQEGDRLS YKRSSSLQRR EISTAPEIIN KPFPENRTRP EVYVPHTVYR NFVNKLASAR GEDASNAMPV LQEVYTAVTY VKIKLPAKLT HISCQQKQGA LPILLNERLQ EKLPPNYSMH PIKWAEGHKG SVHTQDNHLE SQVTFPIRVL HELKLSIICL FLHLVLDKLF GQTANFSQFA LHNSKDLSKD YVHYVFRLPE PTALLDPRSY VSSKLLQARV THSAADEEVK ELALQMVVST AWFFFELLVK KRDSFRRTRF IVNVVTSEIA EQAEKMNISL MDRGFVFNLI LSNLPTLISM HEHYLNLNLF PCPSISSQNS IASMFDLTSE LFTELAAALD RKAVSAIHSL VKPEVKVKIA LDALPQLCDF SGSDEEQEGA IAGNNFNLKT KQYNMLNADT IMKNADQSLI QLNRILDLLF KQSSDKVSTQ RLEEALLRGE APGNDRFPGL THWRQANEKL ALISGNLATE NIIQASSALD RVLVNSLNCD ATLRALIAKF QCFDLCHQVL RSQACATLYL NFARVKMQVT PDFNEEHLRR EDTAMQMTPF LNSILYDTVK LMDLMYRIAK TWLQNMAEKH MCLVHAAALV AEYLSMLEDH QNISSNVLEE DEDGVCAGQY EQAAELFSTG KLVIPILEAH SKLQRAFDSI TYFRVGFFGS VYKEPAITKL YGQCFGAEFV KTKLDPNKAY DEYEMKDRVT FMYTTPFTLE YRRNTVLTTM SVIQKEEFVL KKKTLQLAVA LQMVLQGSVG AQVFLAEIPA LRLCFKEFIM RLITADQREY LKENLRPMIE FRVESQKRDS TQLSQGS SYLPVGSVSF SVVSEDTLSP FTESGLVGLL GLYETVNEVY REFRKLTLTH VNKDHKRMFG KFGDLDEQEF PEISHRLEAF EVIKDSTPVD IQITFVEPYF YFEKNFNLRR GRPRGELHEQ HAFPYIKTRI TPIEVAIEDM INQEPPDAKM ATVNQGPLEV DPKLYRHHNK RCGEAVEKNK QQELKKNYNK RKIPELYKPI FHRSSFRKCE 37 DOCK8 3 Q8NF503 Entry version 160 (18 Sep. 2019) Sequence version 3 (21 Aug. 2007) MTHLNSLDVQ DDLDVVFTPK EEGVELDPHV WLIVNRKNQG GSRKDFHKTL ECSEPAAQAG SGKGPVTACD RLENLLQQVS ARRTNRQAEL DAVEIRPVPE LVKLLTLKFE ALYDVKERKK SDQFKGFLRA ARSAVFSVTY IEKVLQQGEI KESDGGKSKE SFCQRLGKYR SSFFNVSTLE GRSSVGERRT ALSLEENGVG SSFFKQEGDR ADYKRSSSLQ RLEISTAPEI PVKPFPENRT TREVYVPHTV RLNFVNKLAS MCGEDASNAM EFLQEVYTAV EEVKIKLPAK FYHISCQQKQ SWLPILLNER ALEKLPPNYS NPPIKWAEGH VSSVHTQDNH LESQVTFPIR LEHELKLSII VLFLHLVLDK IAGQTANFSQ LAQELGDFTD ECRTLQPSLP RDCVQTYIRE SPEICGFKKT PKQTFESETL PRHLNVLCDV FDLRSLQPDK AEDFEKQNEE FALYPSVDEE CPKEHLGNRI IEIEPLFASI ISENFHCDLN HTPSVAASSQ PSSDIYLVVK GDCAEPYTVI KIEKLKLQAE MPFAWAPISL REVTDVDSW LAQSRRLSER SNFKTSTLSV LSDEDLFKFL RRVKSIPGLL INCCLTPEML RPHKEILEFP YRNLLYVYPQ ARNITIKIQF PVIFGKSSGP TYHNKSPDFY LTVNHHLLFT GASVETLLGY LQTGSYCLPV MHSAEKVPLQ KGVFNIEVQA LEKFFTLCHS VLDQKISEMA CLNSSRLEPL LFQLSVQPMV FAFESVVAIA NSLHNSKDLS ASYVHYVFRL SYHTYGRTSA AAVSSKLLQA AGTHSAADEE DRNCSRMSYY PAAPRPASKK VVSTGMVRET LLVKSMAQHV RTRFSDRFMD SEIAALLVKP NISLAFFLYD FNLIRHYCSQ LISMRLEFLR LNLFFMNADT SQNSSSCSSF LTSEYRQQHF AALDAEGEGI IHSLLSSHDL VKIAALYLPL LCDFTVADTR QEGAGAINQN NLKTSGIVLS NADTTRNLMI QSLIRKWIAD DLLFICVLCF VSTQVLQKSR LRGEGARGEM FPGLNENLRW NEKLDKTKAE LATEAHLIIL SALDCKDSLL LNCDQSTTYL IAKFGDLLFE HQVLHHCSSS TLYLLMRFSF MQVTMSLASL HLRRSLRTIL MTPFPTQVEE DTVKMREFQE RIAKSYQASP AEKHTKKKCY AALVAEYLSM SVSFQNISSN TLSPDEDGVC VGLLEQAAEL NEVYKLVIPI TLTHSKLQRA RMFGTYFRVG EQEFVYKEPA LEAFYGQCFG TPVDKTKLDP EPYFDEYEMK NLRRFMYTTP LHEQYRRNTV KTRISVIQKE IEDMKKKTLQ DAKMLQMVLQ PLEVAQVFLA HHNKLRLCFK KDQHGRNCLL PEVQRDVPKS GAPTALLDPR RVMSSSNPDL VKNIMSSKIA CSGSSDAPSS HFHEELALQM VFKYAWFFFE HNMDKRDSFR DITTIVNVVT QKENEQAEKM LLSLMDRGFV LSAKLSNLPT ILCSHEHYLN APTSPCPSIS QDQKIASMFD LTGLLFTELA SKVQRKAVSA DPRCVKPEVK VGIILDALPQ RYRTSGSDEE VALAIAGNNF SLPYKQYNML CFLWIMKNAD LPSTQLNRIL EYKGKQSSDK DVKARLEEAL MRRRAPGNDR KKEQTHWRQA LDQEALISGN DMQENIIQAS GGVLRVLVNS THCFATLRAL EEVEQCFDLC MDVTRSQACA GATSNFARVK VGRAPDFNEE AYSEEDTAMQ LLCNLNSILY DPEMLMDLMY DLRLTWLQNM TEAAMCLVHA LEDHSYLPVG VLEESVVSED AGQYFTESGL FSTGGLYETV LEAHREFRKL FDSIVNKDHK FFGSKFGDLD ITKLPEISHR AEFVEVIKDS NKAYIQITFV DRVTYFEKNF FTLEGRPRGE LTTMHAFPYI EFVLTPIEVA LAVAINQEPP GSVGATVNQG EIPADPKLYR EFIMRCGEAV EKNKRLITAD NYNKLKENLR YKPIFRVESQ RKCETQLSQG S QREYQQELKK PMIERKIPEL KRDSFHRSSF 38 DOCK8 4 Q8NF504 Entry version 160 (18 Sep. 2019) Sequence version 3 (21 Aug. 2007) MTHLNSLDVQ DDLDVVFTPK EEGVELDPHV WLIVNRKNQG GSRKDFHKTL ECSEPAAQAG SGKGPVTACD RLENLLQQVS ARRTNRQAEL DAVEIRPVPE LVKLLTLKFE ALYDVKERKK SDQFKGFLRA ARSAVFSVTY IEKVLQQGEI KESDGGKSKE SFCQRLGKYR SSFFNVSTLE GRSSVGERRT ALSLEENGVG SSFFKQEGDR ADYKRSSSLQ RLEISTAPEI PVKPFPENRT TREVYVPHTV RLNFVNKLAS MCGEDASNAM EFLQEVYTAV EEVKIKLPAK FYHISCQQKQ SWLPILLNER ALEKLPPNYS NPPIKWAEGH VSSVHTQDNH LESQVTFPIR LEHELKLSII VLFLHLVLDK IAGQTANFSQ NSLHNSKDLS ASYVHYVFRL GAPTALLDPR AAVSSKLLQA AGTHSAADEE DRNCSRMSYY PAAPRPASKK VVSTGMVRET LLVKSMAQHV RTRFSDRFMD SEIAALLVKP NISLAFFLYD FNLIRHYCSQ LISMRLEFLR LNLFFMNADT SQNSSSCSSF LTSEYRQQHF LAQELGDFTD ECRTLQPSLP RDCVQTYIRE SPEICGFKKT PKQTFESETL PRHLNVLCDV FDLRSLQPDK AEDFEKQNEE FALYPSVDEE CPKEHLGNRI IEIEPLFASI ISENFHCDLN HTPSVAASSQ PSSDIYLVVK GDCAEPYTVI KIEKLKLQAE MPFAWAPISL REVTDVDSW LAQSRRLSER SNFKTSTLSV LSDEDLFKFL RRVKSIPGLL INCCLTPEML RPHKEILEFP YRNLLYVYPQ ARNITIKIQF PVIFGKSSGP TYHNKSPDFY LTVNHHLLFT GASVETLLGY LQTGSYCLPV MHSAEKVPLQ KGVFNIEVQA LEKFFTLCHS VLDQKISEMA CLNSSRLEPL LFQLSVQPMV FAFESVVAIA KDQHGRNCLL PEVQRDVPKS SYHTYGRTSA RVMSSSNPDL VKNIMSSKIA CSGSSDAPSS HFHEELALQM VFKYAWFFFE HNMDKRDSFR DITTIVNVVT QKENEQAEKM LLSLMDRGFV LSAKLSNLPT ILCSHEHYLN APTSPCPSIS QDQKIASMFD LTGLLFTELA AALDAEGEGI IHSLLSSHDL VKIAALYLPL LCDFTVADTR QEGAGAINQN NLKTSGIVLS NADTTRNLMI QSLIRKWIAD DLLFICVLCF VSTQVLQKSR LRGEGARGEM FPGLNENLRW NEKLDKTKAE LATEAHLIIL SALDCKDSLL LNCDQSTTYL IAKFGDLLFE HQVLHHCSSS TLYLLMRFSF MQVTMSLASL HLRRSLRTIL MTPFPTQVEE DTVKMREFQE RIAKSYQASP AEKHTKKKCY AALVAEYLSM SVSFQNISSN TLSPDEDGVC VGLLEQAAEL NEVYKLVIPI TLTHSKLQRA RMFGTYFRVG EQEFVYKEPA LEAFYGQCFG TPVDKTKLDP EPYFDEYEMK NLRRFMYTTP LHEQYRRNTV KTRISVIQKE IEDMKKKTLQ DAKMLQMVLQ PLEVAQVFLA HHNKLRLCFK EKNKRLITAD NYNKLKENLR YKPIFRVESQ RKCETQLSQG SKVQRKAVSA DPRCVKPEVK VGIILDALPQ RYRTSGSDEE VALAIAGNNF SLPYKQYNML CFLWIMKNAD LPSTQLNRIL EYKGKQSSDK DVKARLEEAL MRRRAPGNDR KKEQTHWRQA LDQEALISGN DMQENIIQAS GGVLRVLVNS THCFATLRAL EEVEQCFDLC MDVTRSQACA GATSNFARVK VGRAPDFNEE AYSEEDTAMQ LLCNLNSILY DPEMLMDLMY DLRLTWLQNM TEAAMCLVHA LEDHSYLPVG VLEESVVSED AGQYFTESGL FSTGGLYETV LEAHREFRKL FDSIVNKDHK FFGSKFGDLD ITKLPEISHR AEFVEVIKDS NKAYIQITFV DRVTYFEKNF FTLEGRPRGE LTTMHAFPYI EFVLTPIEVA LAVAINQEPP GSVGATVNQG EIPADPKLYR EFIMRCGEAV QREYQQELKK PMIERKIPEL KRDSFHRSSF S 39 COMP 1 P49747 Entry version 195 (18 Sep. 2019) Sequence version 2 (14 Oct. 2008) MVPDTACVLL QGQSPLGSDL TNAALQDVRE FLKNTVMECD GLPSVRPLLH ACIQTESGAR NGSHCTDVNE RCINTSPGFR PTHQGVGLAF INECETGQHN RGSFQCGPCQ CQRRAQRFCP LTLAALGASG GPQMLRELQE LLRQQVREIT ACGMQQSVRT CAPGFCFPGV CGPCPAGFTG CNAHPCFPRV CEACPPGYSG AKANKQVCTD CVPNSVCINT PGFVGDQASG DGSPSECHEH ADCVLERDGS GNGILCGRDT RCPERQCRKD EDVDRDGIGD VPNEKDNCPL EDKWGDACDN DTDQDGRGDA RNQADNCPRV DGIGDACDNC VDHDFVGDAC HQDSRDNCPT HDGQGDACDD RDNCRLVPNP GDVCQDDFDA PENAEVTLTD PEGDAQIDPN VQTMNSDPGL DFEGTFHVNT FGYQDSSSFY YWQANPFRAV KSSTGPGEQL ESQVRLLWKD SYRWFLQHRP EGPELVADSN RLGVFCFSQE CNDTIPEDYE RSCVCAVGWA DLDGFPDEKL NCVTVPNSGQ ACDPDADGDG VRNPDQRNTD CRSQKNDDQK CDDDIDGDRI PNSDQKDSDG PQKSNPDQAD DSDQDQDGDG VPNSAQEDSD DDDNDGVPDS GQEDADRDGV DKVVDKIDVC FRAFQTVVLD WVVLNQGREI AVGYTAFNGV VTDDDYAGFI VVMWKQMEQT AEPGIQLKAV RNALWHTGDT PRNVGWKDKK QVGYIRVRFY VVLDTTMRGG NIIWANLRYR THQLRQA 40 COMP 2 P497472 Entry version 195 (18 Sep. 2019) Sequence version 2 (14 Oct. 2008) MVPDTACVLL QGQSPLGSDL TNAALQDVRE FLKNTVMECD GLPSVRPLLH ACIQTESGAR NGSHCTDVNE NSVCINTRGS VGDQASGCQR PSECHEHADC VCAVGWAGNG GFPDEKLRCP TVPNSGQEDV PDADGDGVPN PDQRNTDEDK QKNDDQKDTD DIDGDRIRNQ DQKDSDGDGI SNPDQADVDH QDQDGDGHQD SAQEDSDHDG NDGVPDSRDN DADRDGVGDV VDKIDVCPEN FQTVVLDPEG LNQGREIVQT YTAFNGVDFE DDYAGFIFGY WKQMEQTYWQ GIQLKAVKSS LWHTGDTESQ VGWKDKKSYR YIRVRFYEGP LTLAALGASG GPQMLRELQE LLRQQVREIT ACGMQQSVRT CAPGFCFPGV CGPCPAGFTG CETGQHNCVP FQCGPCQPGF RAQRFCPDGS VLERDGSRSC ILCGRDTDLD ERQCRKDNCV DRDGIGDACD EKDNCPLVRN WGDACDNCRS QDGRGDACDD ADNCPRVPNS GDACDNCPQK DFVGDACDSD SRDNCPTVPN QGDACDDDDD CRLVPNPGQE CQDDFDADKV AEVTLTDFRA DAQIDPNWW MNSDPGLAVG GTFHVNTVTD QDSSSFYVVM ANPFRAVAEP TGPGEQLRNA VRLLWKDPRN WFLQHRPQVG ELVADSNVVL DTTMRGGRLG WANLRYRCND LRQA VFCFSQENII TIPEDYETHQ 41 ATG7 1 O95352 Entry version 168 (18 Sep. 2019) Sequence version 1 (01 May 1999) MAAATGDPGL ALDVGFWHEL DEAPKDIKGY ARLTLEFSAF CPAIGTLYNT KKLLLEQAAN ALENPVLLNK KYHFYYWFCY LIQGPVGLDQ ECAYDNLCQT IKYDENMVLV QGQRTKITIG PGWPLRNFLV QSVEVVCFRD HSIIFEVKLP AVGWEKNQKG ECMDPKRLAE CWRLVPTLDL LGAGTLGCNV HITFVDNAKI YEFEDCLGGG LQKIFPGVNA GHPVNFSSVT LEQLIESHDV RWLPAVIAAS GFDTFWMRH GDLCPNHPVA ANIPGYKLGC DSTRDRTLDQ VIAGALAVEL GYAIASSSDD LVPHQIRGFL LAFDKCTACS GFNFLAKVFN GLTLLHQETQ ETI SKLQFAPFSS TQKKLNEYRL YYNGDSAGLP DMSAPTPARC NTLESFKTAD EIWESIKSGT FLLLTFADLK PALCLPESLP RFSLKQIEAL EGVTALPYFL SLLKHYSDFF VYDPCNLAQY LAAHRWSSSF RTMQGARDVA EMAFSPDCPK GMGPRMVNLS SSVDLNLKLM DKVVSVKCLL ARTLMGWGVR SYSNPVRQPL KPKALAAADR RGFNMSIPMP LEQARRDVEQ VFLLMDTRES KRKLVINAAL GLKKPKQQGA SADLLGSSLF YFCNDWAPG QCTVSRPGLA MVSVLQHPEG RMNEPPTSLG SRFDNVLPVS SKVLDQYERE SSHSFLEDLT AAEIWDMSDD 42 ATG7 2 O953522 Entry version 168 (18 Sep. 2019) Sequence version 1 (01 May 1999) MAAATGDPGL ALDVGFWHEL DEAPKDIKGY ARLTLEFSAF CPAIGTLYNT KKLLLEQAAN ALENPVLLNK KYHFYYWFCY LIQGPVGLDQ ECAYDNLCQT IKYDENMVLV QGQRTKITIG PGWPLRNFLV QSVEVVCFRD HSIIFEVKLP AVGWEKNQKG ECMDPKRLAE CWRLVPTLDL LGAGTLGCNV SKLQFAPFSS TQKKLNEYRL YYNGDSAGLP DMSAPTPARC NTLESFKTAD EIWESIKSGT FLLLTFADLK PALCLPESLP RFSLKQIEAL EGVTALPYFL SLLKHYSDFF VYDPCNLAQY LAAHRWSSSF RTMQGARDVA EMAFSPDCPK GMGPRMVNLS SSVDLNLKLM DKVVSVKCLL ARTLMGWGVR HITFVDNAKI YEFEDCLGGG LQKIFPGVNA GHPVNFSSVT LEQLIESHDV RWLPAVIAAS GFDTFWMRH GDLCPNHPVA ANIPGYKLGC DSTRDRTLDQ VIAGALAVEL GYAIASSSDD LVPHQVLDQY VFNSSHSFLE ETQAAEIWDM SYSNPVRQPL KPKALAAADR RGFNMSIPMP LEQARRDVEQ VFLLMDTRES KRKLVINAAL GLKKPKQQGA SADLLGSSLF YFCNDWAPG QCTVSRPGLA MVSVLQHPEG RMNEPPTSLG EREGFNFLAK DLTGLTLLHQ SDDETI 43 ATG7 3 O953523 Entry version 168 (18 Sep. 2019) Sequence version 1 (01 May 1999) MAAATGDPGL ALDVGFWHEL DEAPKDIKGY ARLTLEFSAF CPAIGTLYNT KKLLLEQAAN ALENPVLLNK LECAYDNLCQ LIKYDENMVL FQGQRTKITI YPGWPLRNFL FQSVEVVCFR AHSIIFEVKL KAVGWEKNQK SECMDPKRLA MCWRLVPTLD LLGAGTLGCN RHITFVDNAK LYEFEDCLGG RLQKIFPGVN TLEQARRDVE VVFLLMDTRE SRWLPAVIAA LGFDTFVVMR AGDLCPNHPV FANIPGYKLG GDSTRDRTLD AVIAGALAVE GGYAIASSSD GLVPHQIRGF SLAFDKCTAC ETI SKLQFAPFSS TQKKLNEYRL YYNGDSAGLP DMSAPTPARC NTLESFKTAD EIWESIKSGT FLLLTFAIEA TEGVTALPYF VSLLKHYSDF GVYDPCNLAQ VLAAHRWSSS DRTMQGARDV PEMAFSPDCP GGMGPRMVNL ESSVDLNLKL LDKVVSVKCL VARTLMGWGV ISYSNPVRQP GKPKALAAAD ARGFNMSIPM PGHPVNFSSV QLEQLIESHD SKRKLVINAA HGLKKPKQQG ASADLLGSSL CYFCNDVVAP QQCTVSRPGL LMVSVLQHPE DRMNEPPTSL LSRFDNVLPV SSKIWDMSDD 44 SLC2A1 1 P11166 Entry version 230 (18 Sep. 2019) Sequence version 2 (03 Oct. 2006) MEPSSKKLTG LGSLQFGYNT EEFYNQTWVH LTTLWSLSVA FSVGLFVNRF LLAFVSAVLM MLILGRFIIG PMYVGEVSPT QLGIVVGILI GNKDLWPLLL CIVLPFCPES RLMLAVGGAV GVINAPQKVI RYGESILPTT IFSVGGMIGS GRRNSMLMMN GFSKLGKSFE VYCGLTTGFV ALRGALGTLH AQVFGLDSIM SIIFIPALLQ PRFLLINRNE ENRAKSVLKK LQEMKEESRQ ELFRSPAYRQ SQQLSGINAV AGVQQPVYAT TVVSLFVVER LAGMAGCAIL LPWMSYLSIV VGPGPIPWFI PAAIAVAGFS CFQYVEQLCG LVLFFIFTYF DEIASGFRQG ELFHPLGADS LRGTADVTHD MMREKKVTIL PILIAVVLQL FYYSTSIFEK IGSGIVNTAF AGRRTLHLIG MTIALALLEQ AIFGFVAFFE VAELFSQGPR NWTSNFIVGM PYVFIIFTVL KVPETKGRTF GASQSDKTPE QV 45 GZMK 1 P49863 Entry version 152 (18 Sep. 2019) Sequence version 1 (01 Oct. 1996) MTKFSSFSLF VCFNMEIIGG MASIQYGGHH WVLTAAHCQY VLGAHSLSKN KFIPFSRVTS KLQTAAKLNK TSLRSGTKCK SLRPSDTLRE CNSQSYYNGD GDAKGQKDSC KGVFHAIVSG GIYTLLTKKY PHTN FLIVGAYMTH KEVSPHSRPF VCGGVLIDPQ RFTKGQSPTV EASKQTLEIK DPQSNDIMLV HVKMLHIRSK VTGWGATDPD VTVTVLSRKL PFITKDMVCA KGDSGGPLIC GHECGVATKP QTWIKSNLVP 46 S100A9 1 P06702 Entry version 218 (18 Sep. 2019) Sequence version 1 (01 Jan. 1988) MTCKMSQLER QYSVKLGHPD VRKDLQNFLK HIMEDLDTNA MLMARLTWAS PGHHHKPGLG NIETIINTFH TLNQGEFKEL KENKNEKVIE DKQLSFEEFI HEKMHEGDEG EGTP 47 S100A8 1 P05109 Entry version 209 (18 Sep. 2019) Sequence version 1 (01 Jan. 1988) MLTELEKALN LIKGNFHAVY ECPQYIRKKG NTDGAVNFQE AAHKKSHEES SIIDVYHKYS RDDLKKLLET ADVWFKELDI FLILVIKMGV HKE 48 ATM 1 Q13315 Entry version 236 (18 Sep. 2019) Sequence version 4 (22 Jan. 2014) MSLVLNDLLI TERKKEVEKF KHLDRHSDSK FRFLQKYIQK NVSASTQASR VKYFIKCANR LNYIMDTVKD CSNILLKDIL QQQWLELFSV DVHRVLVARI QTDGLNSKFL RQEKSSSGLN KTLAVNFRIR TLLYIWTQHR ELFQLQIYIH GAYESTKWRS NEISHIGSRG VKENLIELMA TRSLEISQSY CCRQLEHDRA KRLIRDPETI QGKYLNWDAV ETECLRIAKP QKKMQEISSL RAPRLKCQEL SSNGAIYGAD SVRKYWCEIS YFRLYLKPSQ IHAVTKGCCS DFFSKAIQCA HILAALTIFL VCELGDEILP LNDSLKEVII HPKGAKTQEK ILYNLYDLLV KYSSGFRNIA DICHQVFNED TTTQRESSDY SVPCKRKKIE QKSQNDFDLV SKYPASLPNC QLLPQQRHGE EVALCQDKRS LKLWNKIWCI QAENFGLLGA REFWKLFTGS CLTLALTTSI QNMCEVNRSF LFYQLEGDLE SNFPHLVLEK KAAMNFFQSV EELSFSEVEE DFLTIVRECG SVHQNLKESL LLNNYSSEIT LLVGVLGCYC YKSELFQKAK TLFKNKTNEE QLCTRCLSNC GFFLRLLTSK SLASFIKKPF DTNGNLMEVE YPDSSVSDAN AINPLAEEYL LKFLCLCVTT ADIRRKLLML SLHLHMYLML LPMEDVLELL RRDQDVCKTI LGQSNMDSEN VIGAFWHLTK ALVNCLKTLL LNVMGKDFPV NHHQVRMLAA KGDSSRLLKA ENAYLKAQEG PETLDEIYNR VLSCSPICEK KENGLEPHLV FGYRRLEDFM WLNLQDTEYN YTNIEDFYRS IRSHFDEVKS SLLTDCFPKI EGTRDSGMAQ MLKSENLLGK PEIVVELLMT QSTDLCDFSG FPSHVIKATF LKSILEILSK AICEQAAETN IYHLFVSLLL WAFVLRDVIY SCIMDVSLRS VCQTAVTYCK VGTLIPLVYE LLKYLVIDNK LLDPFPDHVV LGWEVIKDHL PWLQIATQLI ELSPLLMILS RTPYVLRCLT NLESSQKSDL TFRGISSEQI IIQGSLVEVD ACRPSCPAVC VPGTVKMGIE SLKESIMKWL NSTEVPPILH ILVSLTMKNC PECEHHQKDK LFLQTTFDKM IEKHQSSIGF DRCLLGLSEQ NSETLVRCSR YMGVIAEEEA SLMQCAGESI FRIGSLRNMM TKKSPNKIAS LMNDIADICK DRGEVESMED DQSSMNLFND EPGESQSTIG SKQDLLFLDM AQTNTVSFRA IDSSTLEPTK LKELPGEEYP KPLSNVCSLY LNHVLHVVKN TRDAQGQFLT ERKYIFSVRM EADPYSKWAI NEVFTQFLAD ESINRLFQDT LPLKLQQTAF MREMSHSAEN KSVLLTLIAV QALFALCKSV KKVLEKVSET ASHLDYLVLE LSSFPFILLN CYKVLIPHLV IANQIQEDWK LVNILPYFAY QRETATKVYD QIDHLFISNL LHEPANSSAS DLDPAPNPPH AYISNCHKTK SPDSYQKILL NVYKKHRILK KDIKSGLGGA TLIHYINQRP FSLCCDLLSQ DALENHLHVI QVEVQKQVLD DNENLYITIK FKDLRITQQK IKYSRGPFSL SVYDALPLTR LELHKDQMVD DGIMVKLVVN HTGEKEVLEA IDFSTIAIQH KLFEDKELQW TLVEDCVKVR LATKTGHSFW LAYLQPFRTS DKENPFEGLD NHDIWIKTLT CEILQLLKPM VLPYLIHDIL LLSTHVQGFF SRSTTPANLD LDKKSQRTML RPSSGTIFND VAKVAQSCAA YADKKSMDDQ SQSTTISSLS LQDLLLEIYR CGGGKMLQPI MWGKALVTYD QAGIIQALQN LKGLDYENKD QAAWRNMQWD GTSYHESLYN STFYESLKYA RSLESVYSLY ELESIGELFS VYIKWQKHSQ EPIMALRTVI NSQRECIKDI LARTFKNTQL YNSVSCGVSE AKKEQSLALS ASCAANNPSL CGNWLAETCL LEKAVEVAGN NGKMKAFLSL IENYMKSSEF KEEVGLLREH VQRELELDEL RFLCKAVENY DMWVFRLCSL NGMMKRDGMK YQLAARMGTK LNNLISRISM LALANANRDE SRITKNVPKQ AANRIICTIR EALCDAYIIL QRKGINIPAD DVVVPTMEIK VTIQSFKAEF IIDCVGSDGK DLRQDAVMQQ RNTETRKRKL SQRSGVLEWC LEEINHFLSV LEGLKDLRRQ IMRASQDNPQ LLQLSKMAIN VGSCLGEVGP SKDASYTKAL TFIMLTYLNN SAAVTCLKNI EIYKMTTDPM RKKFLEVPRF DINLWIPLSE CAFLDSGGTK CEVKTDFCQT LQDTNESWRN TSCLRHFSQT SESEHFFRCC AVVDYMRRQK AFWLDLNYLE HFTALLYAEI EKRSLAFEEG EKSKEETGIS SIGEPDSLYG TRLRTYEHEA LETAIPSSTR LGLCHILSVY WCPELEELHY HCTSVSKEVE ALQSLRDREF RVKEVEEMCK PTLSRLQAIG RSVTHRQLSE LLKDSDFSFQ LEILMEKEMD LTKHLVELSI PERAIFQIKQ WQLEEAQVFW ILKQMIKKLD KLTYTECLRV ENPAVIMQTY YDGESSDELR ARFSDTQYQR ENKQALLKRA KIQTNRYTVK ALRALKEDRK INCLLSGEEH WLENSGVSEV IPTYKFLPLM MMGGLGFHEV DHPHHTLFII FLTKPEVARR SSQLDEDRTE SRRPQMVRSV ANLDATQWKT QPITKLKNLE VDHTGEYGNL RLAGGVNLPK ERRQLVKGRD VFQMCNTLLQ TICTYKWPL TGTVPIGEFL VNNEDGAHKR CQKKMMEVQK MDVCQNFQPV DPAIWFEKRL IVGYILGLGD QSAELVHIDL PTPETVPFRL TGVEGVFRRC SQETLLTIVE TMNPLKALYL HPTLNADDQE SFNKVAERVL EEGTVLSVGG DPKNLSRLFP YRPNDFSAFQ KSFEEKYEVF FRYFCMEKFL AYTRSVATSS RHVQNILINE GVAFEQGKIL TRDIVDGMGI CEKTMEVMRN VLLYDPLFDW QQRPEDETEL CKRNLSDIDQ MRLQEKLKGV QVNLLIQQAI GWKAWV 49 IKBKB 1 O14920 Entry version 217 (18 Sep. 2019) Sequence version 1 (01 Jan. 1998) MSWSPSLTTQ LGTGGFGNVI IAIKQCRQEL EIQIMRRLTH EGMQNLAPND GGDLRKYLNQ AILTLLSDIA IIHRDLKPEN IHKIIDLGYA SFVGTLQYLA VTVDYWSFGT PFLPNWQPVQ VDIWSEDLN YPNNLNSVLA LMWHPRQRGT KALDDILNLK TIHTYPVTED QQDTGIPEED LIPDKPATQC TLDMDLVFLF ISPRPQPESV LAFFQLRKVW KEDCNRLQQG NNSCLSKMKN AKLDFFKTSI TEFGITSDKL VELCGRENEV QTDIVDLQRS DDLEEQAREL QRTEGDSQEM FEKKVRVIYT KALELLPKVE KTVVRLQEKR ACSKVRGPVS LSQPGQLMSQ PAKKSEELVA NAIQDTVREQ WLQTEEEEHS TCGAWEMKER RWHNQETGEQ SPRNRERWCL PNVVAARDVP LPLLAMEYCQ FENCCGLREG SALRYLHENR IVLQQGEQRL KELDQGSLCT PELLEQQKYT LAFECITGFR WHSKVRQKSE GTVKFSSSLP ERLEKWLQLM DPTYGPNGCF LVHILNMVTG ESLQSLKARI QELLQEAGLA ISDGKLNEGH DNSKITYETQ SCILQEPKRN GQVWHSIQTL QRAAMMNLLR SMASMSQQLK QIDLEKYSEQ LLAWREMEQA KLLVERMMAL PMGRKQGGTL YRRLREKPRD VRLLLQAIQS QLSKTWCKQ EVVSLMNEDE QKELWNLLKI GSPDSMNASR PSTASNSLPE EAHNLCTLLE DQSFTALDWS CLEQAS 50 IKBKB 2 O149202 Entry version 217 (18 Sep. 2019) Sequence version 1 (01 Jan. 1998) MFSGGCHSPG PGSPPPAPRP IKQCRQELSP QIMRRLTHPN MQNLAPNDLP DLRKYLNQFE LTLLSDIASA HRDLKPENIV FGRPSPAFPA CRQETGEQIA RNRERWCLEI VVAARDVPEG LLAMEYCQGG NCCGLREGAI LRYLHENRII LQQGEQRLIH KIIDLGYAKE VGTLQYLAPE VDYWSFGTLA LPNWQPVQWH IVVSEDLNGT NNLNSVLAER WHPRQRGTDP LDDILNLKLV HTYPVTEDES DTGIPEEDQE PDKPATQCIS DMDLVFLFDN PRPQPESVSC FFQLRKVWGQ DCNRLQQGQR SCLSKMKNSM LDFFKTSIQI FGITSDKLLL LCGRENEVKL DIVDLQRSPM LEEQARELYR TEGDSQEMVR KKVRVIYTQL LELLPKVEEV VVRLQEKRQK SKVRGPVSGS QPGQLMSQPS KKSEELVAEA IQDTVREQDQ QTEEEEHSCL LDQGSLCTSF LLEQQKYTVT FECITGFRPF SKVRQKSEVD VKFSSSLPYP LEKWLQLMLM TYGPNGCFKA HILNMVTGTI LQSLKARIQQ LLQEAGLALI DGKLNEGHTL SKITYETQIS ILQEPKRNLA VWHSIQTLKE AAMMNLLRNN ASMSQQLKAK DLEKYSEQTE AWREMEQAVE LVERMMALQT GRKQGGTLDD RLREKPRDQR LLLQAIQSFE SKTVVCKQKA VSLMNEDEKT ELWNLLKIAC PDSMNASRLS TASNSLPEPA HNLCTLLENA SFTALDWSWL EQAS 51 IKBKB 3 O149203 Entry version 217 (18 Sep. 2019) Sequence version 1 (01 Jan. 1998) MSWSPSLTTQ LGTGGFGNVI SPRNRERWCL EIQIMRRLTH EGMQNLAPND GGDLRKYLNQ AILTLLSDIA IIHRDLKPEN IHKIIDLGYA SFVGTLQYLA VTVDYWSFGT PFLPNWQPVQ HSCNPSTLGG TCGAWEMKER RWHNQETGEQ IAIKQCRQEL PNVVAARDVP LPLLAMEYCQ FENCCGLREG SALRYLHENR IVLQQGEQRL KELDQGSLCT PELLEQQKYT LAFECITGFR CVRMWPGTVA RGRWIS 52 IKBKB 4 O149204 Entry version 217 (18 Sep. 2019) Sequence version 1 (01 Jan. 1998) MSSDGTIRLT PEGMQNLAPN QGGDLRKYLN GAILTLLSDI RIIHRDLKPE LIHKIIDLGY TSFVGTLQYL TVTVDYWSFG RPFLPNWQPV EVDIVVSEDL PYPNNLNSVL MLMWHPRQRG FKALDDILNL GTIHTYPVTE IQQDTGIPEE ALIPDKPATQ HPNVVAARDV DLPLLAMEYC QFENCCGLRE ASALRYLHEN NIVLQQGEQR AKELDQGSLC APELLEQQKY TLAFECITGF QWHSKVRQKS NGTVKFSSSL AERLEKWLQL TDPTYGPNGC KLVHILNMVT DESLQSLKAR DQELLQEAGL CISDGKLNEG HTLDMDLVFL QISPRPQPES NLAFFQLRKV LKEDCNRLQQ RNNSCLSKMK KAKLDFFKTS QTEFGITSDK AVELCGRENE LQTDIVDLQR LDDLEEQARE DQRTEGDSQE SFEKKVRVIY QKALELLPKV EKTVVRLQEK IACSKVRGPV RLSQPGQLMS EPAKKSEELV ENAIQDTVRE SWLQTEEEEH FDNSKITYET VSCILQEPKR WGQVWHSIQT GQRAAMMNLL NSMASMSQQL IQIDLEKYSE LLLAWREMEQ VKLLVERMMA SPMGRKQGGT LYRRLREKPR MVRLLLQAIQ TQLSKTVVCK EEWSLMNED RQKELWNLLK SGSPDSMNAS QPSTASNSLP AEAHNLCTLL QDQSFTALDW SCLEQAS 53 BCAP31 1 P51572 Entry version 186 (18 Sep. 2019) Sequence version 3 (23 Jan. 2007) MSLQWTAVAT LLCIPFISPK VELLVSYGNT LLVIDAVREI NLQNNPGAME RNLYIAGFSL TLISQQATLL ESASEAAKKY AAVDGGKLDV NRSLKADLQK KLEKAENQVL KEYDRLLEEH MDKKEE FLYAEVFVVL RWQKIFKSRL FFVVLIVILV RKYDDVTEKV HFHMKLFRAQ LLSFLLRRLV ASNEAFKKQA MEENDQLKKG GNAEVKLEEE LKDELASTKQ AMRKQSEGLT AKLQAAVDGP 54 BCAP31 2 P515722 Entry version 186 (18 Sep. 2019) Sequence version 3 (23 Jan. 2007) MGAEASSSWC SVKRASEISG ALDVLTHVLE GKPSSNRMSL AEVFVVLLLC KIFKSRLVEL VLIVILVLLV DDVTEKVNLQ MKLFRAQRNL FLLRRLVTLI EAFKKQAESA NDQLKKGAAV EVKLEEENRS ELASTKQKLE KQSEGLTKEY QAAVDGPMDK PGTALPEERL FLGQGSSGEA GAGNKLTSSC QWTAVATFLY IPFISPKRWQ LVSYGNTFFV IDAVREIRKY NNPGAMEHFH YIAGFSLLLS SQQATLLASN SEAAKKYMEE DGGKLDVGNA LKADLQKLKD KAENQVLAMR DRLLEEHAKL KEE 55 TAPBP 1 O15533 Entry version 190 (18 Sep. 2019) Sequence version 1 (01 Jan. 1998) MKSLSLLLAV GPAVIECWFV RPGALLLRQG DPELYLSVHD RYPRGAPAPH ASAKWASGLT GAWLMVSISS PQPEPQQEPV VLTHTPAPRV SFAYMPPTSE PFGLEWRRQH TPGLNGQMPA ALGLATAVSA EDASGKGLAK PGEPPPRPDL PAGALQAAFR CEMSRFVPLP PAQNCPRALD PVLSLSSLLR LITMATVVLT RLGQDALLDL AASSLAPGPP LGKGHLLLAA AQEGAVAFAA WDDDEPWGPW VQPFQEGTYL QVTLELAVYK LARAAPGEAP YPSGGLEVEW QKAEGQRWLS SLSGHLQPPP ACRIHHPSLP EVAGLSGPSL FLLLGLFKAL KDSKKKAE TGNGTFWLPR ATIHLPYLQG PPKVSLMPAT PELLCLVSHF ELRGGPGGRS ALRHHSDGSV VTTEQHGARY ASGRSAEVTL EDSVGLFLSA GWAAVYLSTC 56 TAPBP 2 O155332 Entry version 190 (18 Sep. 2019) Sequence version 1 (01 Jan. 1998) MKSLSLLLAV GPAVIECWFV RPGALLLRQG DPELYLSVHD RYPRGAPAPH ASAKWASGLT GAWLMVSISS PQPEPQQEPV VLTHTPAPRV SFAYMPPTSE PFGLEWRRQH TPGLNGQMPA WDDDEPWGPW VQPFQEGTYL QVTLELAVYK LARAAPGEAP YPSGGLEVEW QKAEGQRWLS SLSGHLQPPP ACRIHHPSLP EVAGKSWELC ALGLATAVSA EDASGKGLAK PGEPPPRPDL PAGALQAAFR CEMSRFVPLP PAQNCPRALD PVLSLSSLLR LITMATVVLT RLGQDALLDL AASSLAPGPP LGKGHLLLAA AQEGAVAFAA TGNGTFWLPR ATIHLPYLQG PPKVSLMPAT PELLCLVSHF ELRGGPGGRS ALRHHSDGSV VTTEQHGARY ASGRSAEVTL GI 58 TAPBP 4 O15533 Entry version MKSLSLLLAV ALGLATAVSA 4 190 (18 Sep. 2019) Sequence version 1 (01 Jan. 1998) GPAVIECWFV RPGALLLRQG DPELYLSVHV PRVRLGQDAL TSEAASSLAP RQHLGKGHLL MPAAQEGAVA GPWTGNGTFW TYLATIHLPY VYKPPKVSLM EAPPELLCLV VEWELRGGPG WLSALRHHSD PPPVTTEQHG SLPASGRSAE PSLEDSVGLF KALGWAAVYL E EDASGKGLAK PGEPPPRPDL VLTVLTHTPA LDLSFAYMPP GPPPFGLEWR LAATPGLNGQ FAAWDDDEPW LPRVQPFQEG LQGQVTLELA PATLARAAPG SHFYPSGGLE GRSQKAEGQR GSVSLSGHLQ ARYACRIHHP VTLEVAGLSG LSAFLLLGLF STCKDSKKKA 59 PPP3CB 1 P16298 Entry version 166 (18 Sep. 2019) Sequence version 2 (01 Feb. 2005) MAAPEPARAA PGADRVVKAV EEVFDLDGIP KEGRVDEEIA LRREKTMIEV HGQFFDLMKL RYLFLGDYVD YLWVLKILYP ECRHLTEYFT ERVYEACMEA NQQFLCVHGG IRRLDRFKEP WSDPSEDFGN TVRGCSYFYN NNLLSIIRAH RKSQTTGFPS LDVYNNKAAV RQFNCSPHPY WSLPFVGEKV CSDDELMTEG RKEIIRNKIR VLREESESVL LPSGVLAGGR IEAEKAIRGF EAKGLDRINE QDGFNSLNTA HTAQ PPPPPPPPPP PFPPTHRLTS RVDVLKNHLV LRIINEGAAI EAPITVCGDI FEVGGSPANT RGYFSIECVL STLFLLRGNH FKQECKIKYS FDSLPLAALL LSPEIHTLDD PAFGPMCDLL EKSQEHFSHN YPAVCEFLQN EAQDAGYRMY LITIFSAPNY LKYENNVMNI WLPNFMDVFT TEMLVNVLSI EDQFDGSAAA AIGKMARVFS TLKGLTPTGM QTLQSATVEA SPPHRICSFE RMPPRKDAVQ HATENHGTGN 60 PPP3CB 2 P162982 Entry version 166 (18 Sep. 2019) Sequence version 2 (01 Feb. 2005) MAAPEPARAA PFPPTHRLTS EEVFDLDGIP KEGRVDEEIA LRREKTMIEV HGQFFDLMKL RYLFLGDYVD GTEDISINPH WVLKILYPST RHLTEYFTFK VYEACMEAFD QFLCVHGGLS RLDRFKEPPA DPSEDFGNEK PPPPPPPPPP PGADRVVKAV RVDVLKNHLV LRIINEGAAI EAPITVCGDI FEVGGSPANT RGYFSIEHVL NNINECVLYL LFLLRGNHEC QECKIKYSER SLPLAALLNQ PEIHTLDDIR FGPMCDLLWS SQEHFSHNTV RGCSYFYNYP LLSIIRAHEA SQTTGFPSLI VYNNKAAVLK FNCSPHPYWL LPFVGEKVTE DDELMTEGED EIIRNKIRAI REESESVLTL SGVLAGGRQT AVPQMDWGTP CREFLLFFSS AVCEFLQNNN QDAGYRMYRK TIFSAPNYLD YENNVMNIRQ PNFMDVFTWS MLVNVLSICS QFDGSAAARK GKMARVFSVL KGLTPTGMLP LQSGNDVMQL HSFANNSHNA CLSS 61 PPP3CB 3 P162983 Entry version 166 (18 Sep. 2019) Sequence version 2 (01 Feb. 2005) MAAPEPARAA PGADRVVKAV EEVFDLDGIP KEGRVDEEIA LRREKTMIEV HGQFFDLMKL RYLFLGDYVD YLWVLKILYP ECRHLTEYFT ERVYEACMEA NQQFLCVHGG IRRLDRFKEP WSDPSEDFGN TVRGCSYFYN NNLLSIIRAH RKSQTTGFPS LDVYNNKAAV RQFNCSPHPY WSLPFVGEKV CSDDELMTEG ARKEIIRNKI SVLREESESV MLPSGVLAGG FSPPHRICSF ERMPPRKDAV AHATENHGTG PPPPPPPPPP PFPPTHRLTS RVDVLKNHLV LRIINEGAAI EAPITVCGDI FEVGGSPANT RGYFSIECVL STLFLLRGNH FKQECKIKYS FDSLPLAALL LSPEIHTLDD PAFGPMCDLL EKSQEHFSHN YPAVCEFLQN EAQDAGYRMY LITIFSAPNY LKYENNVMNI WLPNFMDVFT TEMLVNVLSI EDQFDVGSAA RAIGKMARVF LTLKGLTPTG RQTLQSAIRG EEAKGLDRIN QQDGFNSLNT NHTAQ 62 PPP3CB 4 P162984 Entry version 166 (18 Sep. 2019) Sequence version 2 (01 Feb. 2005) MAAPEPARAA PGADRVVKAV EEVFDLDGIP KEGRVDEEIA LRREKTMIEV HGQFFDLMKL RYLFLGDYVD YLWVLKILYP ECRHLTEYFT ERVYEACMEA NQQFLCVHGG IRRLDRFKEP WSDPSEDFGN TVRGCSYFYN NNLLSIIRAH RKSQTTGFPS LDVYNNKAAV RQFNCSPHPY WSLPFVGEKV CSDDELMTEG ARKEIIRNKI SVLREESESV PPPPPPPPPP PFPPTHRLTS RVDVLKNHLV LRIINEGAAI EAPITVCGDI FEVGGSPANT RGYFSIECVL STLFLLRGNH FKQECKIKYS FDSLPLAALL LSPEIHTLDD PAFGPMCDLL EKSQEHFSHN YPAVCEFLQN EAQDAGYRMY LITIFSAPNY LKYENNVMNI WLPNFMDVFT TEMLVNVLSI EDQFDVGSAA RAIGKMARVF LTLKGLTPTG MLPSGVLAGG AIEAEKAIRG EEAKGLDRIN QQDGFNSLNT NHTAQ RQTLQSATVE FSPPHRICSF ERMPPRKDAV AHATENHGTG 63 ANXA1 1 P04083 Entry version 244 (18 Sep. 2019) Sequence version 2 (23 Jan. 2007) MAMVSEFLKQ YVQTVKSSKG TFNPSSDVAA DEATIIDILT KAAYLQETGK TCHLEEVVLA DELRAAMKGL LASRTNKEIR KRDLAKDITS LSLAKGDRSE SDARALYEAG FNTILTTRSY TKYSKHDMNK EKCLTAIVKC KLHQAMKGVG VSRSEIDMND ISLCQAILDE ALCGGN AWFIENEEQE GPGSAVSPYP LHKAIMVKGV KRNNAQRQQI PLDETLKKAL LLKTPAQFDA GTDEDTLIEI DINRVYREEL DTSGDFRNAL DFGVNEDLAD ERRKGTDVNV PQLRRVFQKY VLDLELKGDI ATSKPAFFAE TRHKALIRIM IKAFYQKMYG TKGDYEKILV 64 PERM 1 P05164 Entry version 221 (18 Sep. 2019) Sequence version 1 (13 Aug. 1987) MGVPFFSSLR GGLTAEMKLL ATPQPSEGAA LVLSSMEEAK RESIKQRLRS YFKQPVAATR VALDLLERKL TDVLTPAQLN QDVGVTCPEQ NNRRSPTLGA AEYEDGFSLP GFPVALARAV QLTPDQERSL HDLDFTPEPA CETSCVQQPP PRIKNQADCI GSNITIRNQI MVYGSEEPLA GLLAVNQRFQ NLHDDPCLLT AGDTRSSEMP REHNRLATEL RLYQEARKIV DYLPLVLGPT SYNDSVDPRI GHTLIQPFMF RLDNRYQPME GGIDPILRGL NQIAVDEIRE LDLPALNMQR AWRRFCGLPQ LRNLKLARKL DIWMGGVSEP LACIIGTQFR ENEGVFSMQQ RIICDNTGIT CMVDLGPCWA LALAGLLAIL PAVLGEVDTS QLVDKAYKER GSASPMELLS TAVRAADYLH RSLWRRPFNV VLSKSSGCAY DKYRTITGMC SNRAFVRWLP YGWTPGVKRN SNEIVRFPTD MFMQWGQLLD ARASFVTGVN CFPLKIPPND PFFRSCPACP NALTSFVDAS RNLRNMSNQL DNGRALLPFD NRSARIPCFL ELTSMHTLLL KSLNPRWDGE GAMVQIITYR AMRKYLPTYR ANVFTNAFRY PNPRVPLSRV FFASWRWLE MATPAKLNRQ RLFEQVMRIG SRDHGLPGYN PETVGQLGTV MEQYGTPNNI LKRKGRVGPL KLRDGDRFWW RQALAQISLP TVSKNNIFMS NSYPRDFVNC WREAS STLPALNLAS 65 PERM 2 P051642 Entry version 221 (18 Sep. 2019) Sequence version 1 (13 Aug. 1987) MELLSYFKQP ADYLHVALDL RPFNVTDVLT SGCAYQDVGV ITGMCNNRRS VRWLPAEYED GVKRNGFPVA RFPTDQLTPD GQLLDHDLDF VTGVNCETSC IPPNDPRIKN CPACPGSNIT FVDASMVYGS MSNQLGLLAV LLPFDNLHDD IPCFLAGDTR HTLLLREHNR RWDGERLYQE IITYRDYLPL LPTYRSYNDS NAFRYGHTLI YQPMEPNPRV RWLEGGIDP KLNRQNQIAV VMRIGLDLPA LPGYNAWRRF QLGTVLRNLK TPNNIDIWMG RVGPLLACII DRFWWENEGV QISLPRIICD NIFMSNSYPR LNLASWREAS VAATRTAVRA LERKLRSLWR PAQLNVLSKS TCPEQDKYRT PTLGASNRAF GFSLPYGWTP LARAVSNEIV QERSLMFMQW TPEPAARASF VQQPPCFPLK QADCIPFFRS IRNQINALTS EEPLARNLRN NQRFQDNGRA PCLLTNRSAR SSEMPELTSM LATELKSLNP ARKIVGAMVQ VLGPTAMRKY VDPRIANVFT QPFMFRLDNR PLSRVFFASW ILRGLMATPA DEIRERLFEQ LNMQRSRDHG CGLPQPETVG LARKLMEQYG GVSEPLKRKG GTQFRKLRDG FSMQQRQALA NTGITTVSKN DFVNCSTLPA 66 PERM 3 P051643 Entry version 221 (18 Sep. 2019) Sequence version 1 (13 Aug. 1987) MGVPFFSSLR GGLTAEMKLL ATPQPSEGAA LVLSSMEEAK RESIKQRLRS YFKQPVAATR VALDLLERKL TDVLTPAQLN QDVGVTCPEQ NNRCGWLGVA TPQASRCQRP GASNRAFVRW LPYGWTPGVK AVSNEIVRFP SLMFMQWGQL PAARASFVTG PPCFPLKIPP CIPFFRSCPA QINALTSFVD LARNLRNMSN FQDNGRALLP LTNRSARIPC MPELTSMHTL ELKSLNPRWD CMVDLGPCWA LALAGLLAIL PAVLGEVDTS QLVDKAYKER GSASPMELLS TAVRAADYLH RSLWRRPFNV VLSKSSGCAY DKYRTITGMC AGTGLREASR VLPCRRSPTL LPAEYEDGFS RNGFPVALAR TDQLTPDQER LDHDLDFTPE VNCETSCVQQ NDPRIKNQAD CPGSNITIRN ASMVYGSEEP QLGLLAVNQR FDNLHDDPCL FLAGDTRSSE LLREHNRLAT GERLYQEARK IVGAMVQIIT PTAMRKYLPT RIANVFTNAF MFRLDNRYQP RVFFASWRVV GLMATPAKLN RERLFEQVMR QRSRDHGLPG PQPETVGQLG KLMEQYGTPN EPLKRKGRVG FRKLRDGDRF QQRQALAQIS ITTVSKNNIF NCSTLPALNL YRDYLPLVLG YRSYNDSVDP RYGHTLIQPF MEPNPRVPLS LEGGIDPILR RQNQIAVDEI IGLDLPALNM YNAWRRFCGL TVLRNLKLAR NIDIWMGGVS PLLACIIGTQ WWENEGVFSM LPRIICDNTG MSNSYPRDFV ASWREAS 67 PLEC 1 Q15149 Entry version 224 (18 Sep. 2019) Sequence version 3 (14 Oct. 2008) MVAGMLMPRD REGVMVAKKD PGVTNLQVMR VRETFAWCHF HLRQYLHLPP RRPVAMVMPA GPLGSPPKRG RRKELEEVSP RTLARPGPEP QKKTFTKWVN SDLYEDLRDG SGDSLPREKG QIALDYLRHR DIADGNPKLT FQISDIQVSG LLLWSQRMVE TSSWRDGRLF LIDMNKVYRQ SVAERDLGVT PQPDEKSIIT RVPDVQDGVR YRELVLLLLQ ERRFPSSFEE FKEMELPAKE QSLEGAVQAG LDVEKEWGKL LRSEFERLEC EAGLCEEQLN RLLAAGKVPQ KADSMIRLLF HPQGEQMYRR IRTEYNLRLK AQVTLQSVQR YLQDLLAWVE WGVDLPSVEA SIEEFRAKIE PATRGAYRDC LLNSSKARLR AATKELMWLN WSDRNTNMTA ELELKEKKIK REDHPARPTV WSWMLQLCCC YFQFFSDVRE ALRRKYSCDR QLRAIYEVLF RRPRSLHPHV AMASLRARGL YWYLTNEGIA EIVPASLQRV RRTPHVQAVQ PLPTEEQRVY ETPWPATTQ APATDERDRV KHLIKAQRHI HNLISLLEVL RMRFHKLQNV QVKLVNIRND LGLIWTIILH QSEDMTAKEK GYQGLRCDNF NAIIHRHKPL TNLENLDQAF RLLDPEDVDV YVSSLYDAMP ANELQLRWQE WMRHHTAAFE IEILWSQFLK ADKNRSKGIY QLKVPPGYHP HVAILEREKQ LQRIVTKLQM QADALLQSDV RAGEVERDLD NDVQTLKDGR VYRLHERLVA AGVAAPATQV RPELEDSTLR ENQHRVDGAE QLGSHRGLHQ RARSDEGQLS LGRLDLQYAK SLESLHSFVA EKEEEEVGFD KKESYSALMR ELQNAGDRLL ESFQAALQTQ IEAHLKENAA AEGQLQKLQE SATVTRLEDL LQDAQDEKEQ LAKRAKAVVQ RGRLPLLAVC KGDECQLVGP SSGSEAAVPS EAQEAVTRLE HQLHVDMKSL QLIRSWSLAT QALHSLELHY GGFGPEDRLM HYQQLLQSLE RCISELKDIR VHRLRLPLDK AEQQKAQAEV SAEAEKVLAL RSELELTLGK YLEKLKTISL VLRAHEEQLK ELEATKASLK PTFDALRDEL QQRHGERDVE LLERWQAVLA QLGRQLRYYR QDARRRQEQI VREQLRQEQA KVEECQRFAK LQLVTYKAQL KVQSGSESVI SELTTLTSQY MEEEERLAEQ EVEAALEKQR AQAEREAKEL REEAAVDAQQ QLRQSSEAEI IRVVRLQLEA TERQRGGAEG EAEAQKRQAQ EVELASRVKA ALQALEELRL QAEEAERRLR QVALETAQRS SFAEKTAQLE AQLREEAERR REEAERELER LRLQAEEVAQ KQKEEAEREA VRQRELAEQE TAQQRLAAEQ QGEQQRQLLE AAATQKRQEL MEVLLASKAR KSKQRLEAEA ARLRALAEEA AARQRAEAER EATRLKTEAE ERLRRLAEDE AAQHKADIEE SELERQKGLV EEEILALKAS LELELGRIRS LNEYKGHLSG LKPRHPAHPM DYKQVEVTVH AQPSHWKVLS VCFLVPPPNQ AQHQALVTLW LAWQSLRRDV FRTLKPEEQR QAFLRDSQDA AEREYGSCSH QGAQEESRCQ LQLEACETRT EPARECAQRI EGLGKGVARL PEPSPAAPTL LEQVRSLSAI VIRGTQGAEE EAQAVPATLP KLRAQAEAQQ RGAQEVGERL VERWRERVAQ QTDVRQRELE ESADPLGAWL QAMPLADSQA LLEEIERHGE QYINAIKDYE EPVASPAKKP QEYVDLRTHY IKFISETLRR QRAEERERLA QLAEAHAQAK QQRMQEEWR QKRSIQEELQ QAKARQAEAA ERSRLRIEEE ELQALRARAE EEAERLRRQV QDESQRKRQA EAEAAREKQR QAEVERARQV AEAELQSKRA RSLQEEHVAV AQQQAEAERA WQLKANEALR QKSLAQAEAE RRRGKAEEQA LEKQRQLAEG ELIRLRAETE EELARLQREA EAELAKVRAE AEEESRSTSE GRFRELAEEA KRQRQLAEED VLAEKLAAIG IALKEKEAEN AFQRRRLEEQ RLAQLRKASD EDTLRQRRQV FEKAAAGKAE NAEDTLRSKE QAELEAARQR REAEERVQKS RKAALEEVER LRERAEQESA QKRLQAEEKA ELQQTLQQEQ EAARRAAEEA AAQSRRQVEE QAQARAQAQA QEAARRAQAE DAEMEKHKKF VEQELTTLRL LLDEELQRLK SQVEEELFSV KARIEAENRA RFLQEEAEKM SVAAQEAARL QRALAEKMLK RLKAEAELLQ RRLQEDKEQM FQRTLEAERQ RLKLRVAEMS QRFRKQAEEI TQEKVTLVQT DAERLREAIA QEAKLLQLKS LLQETQALQQ QRERFIEQEK VAKAQQLREE ERQRLVASME EGVRRKQEEL EELLAEENQR QHRAALAHSE KTLPNGRDAL HSFDGLRRKV LSAEELQRLA RREDVRHYLQ KATNEKLSVY GTALILLEAQ RNRRLTVNEA HHKLLSAERA QQISLFQAMQ RLLEAQIATG VPVDVAYRRG ADPSDDTKGF YLQLLERCVE LTDKAAKGGE VFEKATVSAP IWEIINSEYF QFRTGRITVE EEQEQKGRLC AELLESRVID ERSVRDVAEV NVIAGVWLEE LKKDLLPSDM TGHIIDPATS AGLVGPEFHE GYRDPYTGQS LIPREQGLRL VDPSKSHRVP QLAAEEERRR LAAEEEAARQ LKAKVEEARR RQLQLAQEAA HAFAVQQKEQ SVLDQLRGEA EEARVQAERE AERLKQSAEE AAEKLRKEAE QAALRQKQAA AEQTLRQKAQ QLEETDHQKN AEATEAARQR RVQMEELSKL LILRDKDNTQ KQVAEEAARL RQLAEEDLAQ EKMQAVQEAT QQKELAQEQA AQQLAEETQG RQLEMSAEAE RAQARAEEDA GEKLHRTELA LEIQRQQSDH ELEREKEKLQ EEMQTVQQEQ SFLSEKDSLL AKLEQLFQDE QQRQQQQMEQ EARRRQHEAE QQLEQQRRQQ LREQLQLLEE EVTASQVAAT DGPAAEAEPE SAQRLQEAGI QGHTTVDELA GRSSIAGLLL AALQRQLLSP AASGFLLDPV VKEGVVGPEL VTGYKDPYTG KGLIVREHGI GVIDPVHSHR YFDEEMNRVL FDPNTHENLT DPETGLCLLP LVYTDSEARD FGKFQGKTVT TAEQRRDLLR KIIKIIITVV FEGLRSLVPA RELYQQLQRG DTVRRALRGA AGQKLSIYNA AVALLEAQAG ARLTVDEAVR KLLSAEKAVT VSLFQALKKG LDAQLSTGGI LDVACARGCL DEETSRALSA PSTGEPATYG LTGLSLLPLS LYSELQARET GGFKGRTVTV AEQRQELLRQ VIKILITIVE SFSGLRAPVP SRAQFEQLKD LGSVRTLLQG DTKEKVSIYE TAALLLEAQA NQRLYVHEAV EQLLSAEKAV TISLFQAMQK LLEAQIATGG PVDVAYQRGY DPSDDTKGFF RQLLERCVED KCAEKAEVVE RRAFEETQID TMSLWEVMQS LMADFQAGRV EIIEKTEIIR RRRLTAEDLF NLLREGTRSL CYLYGTGSVA LSIYQALKKG LEAQAATGFL VDEAVRKGLV AERAVTGYRD QAMKKELIPT LATGGIVDPR YQRGYLNKDT RSYVDPSTDE CRRDDGTGQL TFRGLRKQIT DEATALQLRE NLQKFLEGTS KERLSVYQAM FELLEAQAAT KLTVEEAVRM LLSAERAVTG SLFQAMKKGL EAQIATGGII EVAYKRGLFD SDDTKGFFDP LMERCITDPQ KKRERKTSSK VDPETGKEMS DHQTYLELSE SSSDGVVKSM DIDDAIAKNL AGTLSITEFA RSRSSSVGSS RTQLASWSDP LDTETLEKVS DNITGQRLLE PSTGERFPVT IMVDRINLAQ PRADAKAYSD ELQQRCRPDQ EKAARARQEE FEKTPVEVPV WELISSEYFT FRTGKVTVEK EVETLRQERL ASELLASGVL GKTTVKDLSE SGCLAGIYLE AMRRGLLRAT ATGFLVDPVR KAGVVGPELH TGYRDPYSGS GLVLRQHGIR IIDPVHSHRV FSEEMNRVLA DPNTHENLTY PETGLRLLPL TTQVYTEEET IPGGGSHGGS DLIPEEQRAQ TKERMIIIII QQGLASYDYV EARIISLETY REALEAESAW GVYLPGSRQT LLSAEVARLL LDPVKGERLT GPELHDRLLS PYTEQTISLF EEALRLLDAQ LGFHLPLEVA HDQLSEPSEV RLSYTQLLRR LLPLSDARKL MEELVRSQVM GLTSIEEVTK CIAGVFVDAT KKGIIRPGTA GYVIDPIKGL GIVGPEFKDK YKDPYSGKLI ILKDHGIRLL DPEESHRLPV EEMNEILTDP NTEENLTYLQ TGLCLLPLKE SSVRKRRVVI VYEAYRKGLI QECEWEEITI IIDRRSGRQY IDRSALDQYR DMLSGNAGGF SSYPISPAVS TEETGPVAGI ITEAMHRNLV AQACTGGIID DAVNKGLVDK KAFCGFEDPR TKTKMSAAQA GQRFLEVQYL GRVPLDEALQ KLRDVGAYSK ISYKDALDRS LEAAAQSTKG GSTAGSRTGS GSFDATGSGF SSGYGRRYAS SAVA LKKGWLYYEA TGGLIEPDTP RGTVDARTAQ YLTCPKTKLK MVEEGTGLRL YYSPYSVSGS RTGSRAGSRR SMTFSSSSYS GSSASLGGPE 68 PLEC 2 Q151492 Entry version 224 (18 Sep. 2019) Sequence version 3 (14 Oct. 2008) MSGEDAEVRA GSPSPGDTLP RSGGGAGSNG IRIADERDRV KHLIKAQRHI HNLISLLEVL RMRFHKLQNV QVKLVNIRND LGLIWTIILH QSEDMTAKEK GYQGLRCDNF NAIIHRHKPL TNLENLDQAF RLLDPEDVDV YVSSLYDAMP ANELQLRWQE WMRHHTAAFE IEILWSQFLK ADKNRSKGIY QLKVPPGYHP HVAILEREKQ LQRIVTKLQM QADALLQSDV RAGEVERDLD NDVQTLKDGR VYRLHERLVA AGVAAPATQV RPELEDSTLR ENQHRVDGAE QLGSHRGLHQ RARSDEGQLS LGRLDLQYAK SLESLHSFVA EKEEEEVGFD KKESYSALMR ELQNAGDRLL ESFQAALQTQ IEAHLKENAA AEGQLQKLQE SATVTRLEDL LNEYKGHLSG LKPRHPAHPM DYKQVEVTVH AQPSHWKVLS VCFLVPPPNQ AQHQALVTLW LAWQSLRRDV FRTLKPEEQR QAFLRDSQDA AEREYGSCSH VSEDVSNGSS WNLGKTQRSR SVLDPAERAV QKKTFTKWVN SDLYEDLRDG SGDSLPREKG QIALDYLRHR DIADGNPKLT FQISDIQVSG LLLWSQRMVE TSSWRDGRLF LIDMNKVYRQ SVAERDLGVT PQPDEKSIIT RVPDVQDGVR YRELVLLLLQ ERRFPSSFEE FKEMELPAKE QSLEGAVQAG LDVEKEWGKL LRSEFERLEC EAGLCEEQLN RLLAAGKVPQ KADSMIRLLF HPQGEQMYRR IRTEYNLRLK AQVTLQSVQR YLQDLLAWVE WGVDLPSVEA SIEEFRAKIE PATRGAYRDC LLNSSKARLR AATKELMWLN WSDRNTNMTA ELELKEKKIK REDHPARPTV WSWMLQLCCC YFQFFSDVRE ALRRKYSCDR LQDAQDEKEQ LAKRAKAVVQ RGRLPLLAVC KGDECQLVGP SSGSEAAVPS EAQEAVTRLE HQLHVDMKSL QLIRSWSLAT QALHSLELHY GGFGPEDRLM HYQQLLQSLE QGAQEESRCQ LQLEACETRT EPARECAQRI EGLGKGVARL PEPSPAAPTL LEQVRSLSAI VIRGTQGAEE EAQAVPATLP KLRAQAEAQQ RGAQEVGERL VERWRERVAQ QTDVRQRELE ESADPLGAWL QAMPLADSQA LLEEIERHGE QYINAIKDYE EPVASPAKKP QEYVDLRTHY IKFISETLRR QRAEERERLA QLAEAHAQAK QQRMQEEWR QKRSIQEELQ QAKARQAEAA IRVVRLQLEA ELQALRARAE EEAERLRRQV EVELASRVKA ALQALEELRL QAEVERARQV AEAELQSKRA RSLQEEHVAV AQQQAEAERA WQLKANEALR QKSLAQAEAE RRRGKAEEQA LEKQRQLAEG ELIRLRAETE EELARLQREA EAELAKVRAE AEEESRSTSE GRFRELAEEA KRQRQLAEED VLAEKLAAIG IALKEKEAEN AFQRRRLEEQ RLAQLRKASD EDTLRQRRQV FEKAAAGKAE NAEDTLRSKE QLAAEEERRR LAAEEEAARQ LKAKVEEARR RQLQLAQEAA HAFAVQQKEQ SVLDQLRGEA EEARVQAERE AERLKQSAEE AAEKLRKEAE QAALRQKQAA RCISELKDIR VHRLRLPLDK AEQQKAQAEV SAEAEKVLAL RSELELTLGK YLEKLKTISL VLRAHEEQLK ELEATKASLK PTFDALRDEL QQRHGERDVE LLERWQAVLA QLGRQLRYYR QDARRRQEQI VREQLRQEQA KVEECQRFAK LQLVTYKAQL KVQSGSESVI SELTTLTSQY MEEEERLAEQ EVEAALEKQR AQAEREAKEL REEAAVDAQQ QLRQSSEAEI ERSRLRIEEE TERQRGGAEG EAEAQKRQAQ QDESQRKRQA EAEAAREKQR QAEEAERRLR QVALETAQRS SFAEKTAQLE AQLREEAERR REEAERELER LRLQAEEVAQ KQKEEAEREA VRQRELAEQE TAQQRLAAEQ QGEQQRQLLE AAATQKRQEL MEVLLASKAR KSKQRLEAEA ARLRALAEEA AARQRAEAER EATRLKTEAE ERLRRLAEDE AAQHKADIEE SELERQKGLV EEEILALKAS LELELGRIRS QAELEAARQR REAEERVQKS RKAALEEVER LRERAEQESA QKRLQAEEKA ELQQTLQQEQ EAARRAAEEA AAQSRRQVEE QAQARAQAQA QEAARRAQAE DAEMEKHKKF AEQTLRQKAQ QLEETDHQKN AEATEAARQR RVQMEELSKL LILRDKDNTQ KQVAEEAARL RQLAEEDLAQ EKMQAVQEAT QQKELAQEQA AQQLAEETQG RQLEMSAEAE RAQARAEEDA GEKLHRTELA LEIQRQQSDH ELEREKEKLQ EEMQTVQQEQ SFLSEKDSLL AKLEQLFQDE QQRQQQQMEQ EARRRQHEAE QQLEQQRRQQ LREQLQLLEE EVTASQVAAT DGPAAEAEPE SAQRLQEAGI QGHTTVDELA GRSSIAGLLL AALQRQLLSP AASGFLLDPV VKEGVVGPEL VTGYKDPYTG KGLIVREHGI GVIDPVHSHR YFDEEMNRVL FDPNTHENLT DPETGLCLLP LVYTDSEARD FGKFQGKTVT TAEQRRDLLR KIIKIIITVV FEGLRSLVPA RELYQQLQRG DTVRRALRGA AGQKLSIYNA AVALLEAQAG ARLTVDEAVR KLLSAEKAVT VSLFQALKKG LDAQLSTGGI LDVACARGCL PRADAKAYSD ELQQRCRPDQ EKAARARQEE FEKTPVEVPV WELISSEYFT FRTGKVTVEK EVETLRQERL ASELLASGVL GKTTVKDLSE SGCLAGIYLE VEQELTTLRL LLDEELQRLK SQVEEELFSV KARIEAENRA RFLQEEAEKM SVAAQEAARL QRALAEKMLK RLKAEAELLQ RRLQEDKEQM FQRTLEAERQ RLKLRVAEMS QRFRKQAEEI TQEKVTLVQT DAERLREAIA QEAKLLQLKS LLQETQALQQ QRERFIEQEK VAKAQQLREE ERQRLVASME EGVRRKQEEL EELLAEENQR QHRAALAHSE KTLPNGRDAL HSFDGLRRKV LSAEELQRLA RREDVRHYLQ KATNEKLSVY GTALILLEAQ RNRRLTVNEA HHKLLSAERA QQISLFQAMQ RLLEAQIATG VPVDVAYRRG ADPSDDTKGF YLQLLERCVE LTDKAAKGGE VFEKATVSAP IWEIINSEYF QFRTGRITVE EEQEQKGRLC AELLESRVID ERSVRDVAEV NVIAGVWLEE LKKDLLPSDM TGHIIDPATS AGLVGPEFHE GYRDPYTGQS LIPREQGLRL VDPSKSHRVP DEETSRALSA PSTGEPATYG LTGLSLLPLS LYSELQARET GGFKGRTVTV AEQRQELLRQ VIKILITIVE SFSGLRAPVP SRAQFEQLKD LGSVRTLLQG DTKEKVSIYE AMRRGLLRAT ATGFLVDPVR KAGVVGPELH TGYRDPYSGS GLVLRQHGIR IIDPVHSHRV FSEEMNRVLA DPNTHENLTY PETGLRLLPL TTQVYTEEET IPGGGSHGGS DLIPEEQRAQ TKERMIIIII QQGLASYDYV EARIISLETY REALEAESAW GVYLPGSRQT LLSAEVARLL LDPVKGERLT GPELHDRLLS PYTEQTISLF EEALRLLDAQ LGFHLPLEVA HDQLSEPSEV RLSYTQLLRR LLPLSDARKL MEELVRSQVM GLTSIEEVTK CIAGVFVDAT KKGIIRPGTA GYVIDPIKGL GIVGPEFKDK YKDPYSGKLI ILKDHGIRLL DPEESHRLPV EEMNEILTDP NTEENLTYLQ TGLCLLPLKE SSVRKRRVVI VYEAYRKGLI QECEWEEITI IIDRRSGRQY IDRSALDQYR DMLSGNAGGF SSYPISPAVS TEETGPVAGI ITEAMHRNLV AQACTGGIID DAVNKGLVDK KAFCGFEDPR LKKGWLYYEA TGGLIEPDTP RGTVDARTAQ YLTCPKTKLK MVEEGTGLRL YYSPYSVSGS RTGSRAGSRR SMTFSSSSYS GSSASLGGPE TAALLLEAQA NQRLYVHEAV EQLLSAEKAV TISLFQAMQK LLEAQIATGG PVDVAYQRGY DPSDDTKGFF RQLLERCVED KGAEKAEVVE RRAFEETQID TMSLWEVMQS LMADFQAGRV EIIEKTEIIR RRRLTAEDLF NLLREGTRSL CYLYGTGSVA LSIYQALKKG LEAQAATGFL VDEAVRKGLV AERAVTGYRD QAMKKELIPT LATGGIVDPR YQRGYLNKDT RSYVDPSTDE CRRDDGTGQL TFRGLRKQIT DEATALQLRE NLQKFLEGTS KERLSVYQAM FELLEAQAAT KLTVEEAVRM LLSAERAVTG SLFQAMKKGL EAQIATGGII EVAYKRGLFD SDDTKGFFDP LMERCITDPQ KKRERKTSSK VDPETGKEMS DHQTYLELSE SSSDGVVKSM DIDDAIAKNL AGTLSITEFA RSRSSSVGSS RTQLASWSDP LDTETLEKVS DNITGQRLLE PSTGERFPVT IMVDRINLAQ TKTKMSAAQA GQRFLEVQYL GRVPLDEALQ KLRDVGAYSK ISYKDALDRS LEAAAQSTKG GSTAGSRTGS GSFDATGSGF SSGYGRRYAS SAVA 69 PLEC 3 Q15149-3 Entry version MSGEDAEVRA VSEDVSNGSS 224 (18 Sep. 2019) Sequence version 3 (14 Oct. 2008) GSPSPGDTLP RSGGGAGSNG IRIADERDRV KHLIKAQRHI HNLISLLEVL RMRFHKLQNV QVKLVNIRND LGLIWTIILH QSEDMTAKEK GYQGLRCDNF NAIIHRHKPL TNLENLDQAF RLLDPEDVDV YVSSLYDAMP QLRWQEYREL HTAAFEERRF WSQFLKFKEM RSKGIYQSLE PPGYHPLDVE LEREKQLRSE VTKLQMEAGL LLQSDVRLLA VERDLDKADS TLKDGRHPQG HERLVAIRTE APATQVAQVT EDSTLRYLQD RVDGAEWGVD HRGLHQSIEE DEGQLSPATR DLQYAKLLNS LHSFVAAATK EEVGFDWSDR YSALMRELEL AGDRLLREDH AALQTQWSWM LKENAAYFQF LQKLQEALRR TRLEDLLQDA KGHLSGLAKR HPAHPMRGRL VEVTVHKGDE HWKVLSSSGS VPPPNQEAQE ALVTLWHQLH SLRRDVQLIR KPEEQRQALH RDSQDAGGFG YGSCSHHYQQ EESRCQRCIS ACETRTVHRL ECAQRIAEQQ KGVARLSAEA PAAPTLRSEL RSLSAIYLEK TQGAEEVLRA VPATLPELEA QAEAQQPTFD EVGERLQQRH RERVAQLLER WNLGKTQRSR SVLDPAERAV QKKTFTKWVN SDLYEDLRDG SGDSLPREKG QIALDYLRHR DIADGNPKLT FQISDIQVSG LLLWSQRMVE TSSWRDGRLF LIDMNKVYRQ SVAERDLGVT PQPDEKSIIT RVPDVQDGEL VLLLLQWMRH PSSFEEIEIL ELPAKEADKN GAVQAGQLKV KEWGKLHVAI FERLECLQRI CEEQLNQADA AGKVPQRAGE MIRLLFNDVQ EQMYRRVYRL YNLRLKAGVA LQSVQRRPEL LLAWVEENQH LPSVEAQLGS FRAKIERARS GAYRDCLGRL SKARLRSLES ELMWLNEKEE NTNMTAKKES KEKKIKELQN PARPTVESFQ LQLCCCIEAH FSDVREAEGQ KYSCDRSATV QDEKEQLNEY AKAVVQLKPR PLLAVCDYKQ CQLVGPAQPS EAAVPSVCFL AVTRLEAQHQ VDMKSLLAWQ SWSLATFRTL SLELHYQAFL PEDRLMAERE LLQSLEQGAQ ELKDIRLQLE RLPLDKEPAR KAQAEVEGLG EKVLALPEPS ELTLGKLEQV LKTISLVIRG HEEQLKEAQA TKASLKKLRA ALRDELRGAQ GERDVEVERW WQAVLAQTDV RQRELEQLGR PLGAWLQDAR LADSQAVREQ IERHGEKVEE AIKDYELQLV SPAKKPKVQS DLRTHYSELT SETLRRMEEE ERERLAEVEA AHAQAKAQAE QEEWRREEA IQEELQQLRQ RQAEAAERSR RLQLEATERQ LRARAEEAEA RLRRQVQDES ASRVKAEAEA LEELRLQAEE ERARQVQVAL LQSKRASFAE EEHVAVAQLR AEAERAREEA ANEALRLRLQ AQAEAEKQKE KAEEQAVRQR RQLAEGTAQQ LRAETEQGEQ RLQREAAAAT AKVRAEMEVL SRSTSEKSKQ ELAEEAARLR QLAEEDAARQ KLAAIGEATR EKEAENERLR RRLEEQAAQH LRKASDSELE RQRRQVEEEI AAGKAELELE TLRSKEQAEL EEERRRREAE EEAARQRKAA VEEARRLRER LAQEAAQKRL VQQKEQELQQ QLRGEAEAAR VQAEREAAQS KQSAEEQAQA LRKEAEQEAA RQKQAADAEM LRQKAQVEQE TDHQKNLLDE EAARQRSQVE EELSKLKARI DKDNTQRFLQ EEAARLSVAA EEDLAQQRAL AVQEATRLKA LAQEQARRLQ AEETQGFQRT MSAEAERLKL QLRYYRESAD RRQEQIQAMP LRQEQALLEE CQRFAKQYIN TYKAQLEPVA GSESVIQEYV TLTSQYIKFI ERLAEQQRAE ALEKQRQLAE REAKELQQRM AVDAQQQKRS SSEAEIQAKA LRIEEEIRVV RGGAEGELQA QKRQAQEEAE QRKRQAEVEL AREKQRALQA AERRLRQAEV ETAQRSAEAE KTAQLERSLQ EEAERRAQQQ ERELERWQLK AEEVAQQKSL EAEREARRRG ELAEQELEKQ RLAAEQELIR QRQLLEEELA QKRQELEAEL LASKARAEEE RLEAEAGRFR ALAEEAKRQR RAEAERVLAE LKTEAEIALK RLAEDEAFQR KADIEERLAQ RQKGLVEDTL LALKASFEKA LGRIRSNAED EAARQRQLAA ERVQKSLAAE LEEVERLKAK AEQESARQLQ QAEEKAHAFA TLQQEQSVLD RAAEEAEEAR RRQVEEAERL RAQAQAAAEK RRAQAEQAAL EKHKKFAEQT LTTLRLQLEE ELQRLKAEAT EELFSVRVQM EAENRALILR EEAEKMKQVA QEAARLRQLA AEKMLKEKMQ EAELLQQQKE EDKEQMAQQL LEAERQRQLE RVAEMSRAQA RAEEDAQRFR HRTELATQEK RQQSDHDAER EKEKLQQEAK TVQQEQLLQE EKDSLLQRER QLFQDEVAKA QQQMEQERQR RQHEAEEGVR QQRRQQEELL LQLLEEQHRA SQVAATKTLP AEAEPEHSFD LQEAGILSAE TVDELARRED IAGLLLKATN RQLLSPGTAL FLLDPVRNRR VVGPELHHKL KDPYTGQQIS VREHGIRLLE PVHSHRVPVD EMNRVLADPS THENLTYLQL GLCLLPLTDK DSEARDVFEK QGKTVTIWEI RRDLLRQFRT IIITVVEEQE RSLVPAAELL QQLQRGERSV RALRGANVIA LSIYNALKKD LEAQAGTGHI VDEAVRAGLV AEKAVTGYRD QALKKGLIPR LSTGGIVDPS CARGCLDEET AKAYSDPSTG RCRPDQLTGL RARQEELYSE PVEVPVGGFK SSEYFTAEQR KVTVEKVIKI LRQERLSFSG LASGVLSRAQ VKDLSELGSV AGIYLEDTKE GLLRATTAAL LVDPVRNQRL VGPELHEQLL DPYSGSTISL RQHGIRLLEA VHSHRVPVDV MNRVLADPSD HENLTYRQLL LRLLPLKGAE YTEEETRRAF GSHGGSTMSL KQAEEIGEKL VTLVQTLEIQ LREAIAELER LLQLKSEEMQ TQALQQSFLS FIEQEKAKLE QQLREEQQRQ LVASMEEARR RKQEELQQLE AEENQRLREQ ALAHSEEVTA NGRDALDGPA GLRRKVSAQR ELQRLAQGHT VRHYLQGRSS EKLSVYAALQ ILLEAQAASG LTVNEAVKEG LSAERAVTGY LFQAMQKGLI AQIATGGVID VAYRRGYFDE DDTKGFFDPN LERCVEDPET AAKGGELVYT ATVSAPFGKF INSEYFTAEQ GRITVEKIIK QKGRLCFEGL ESRVIDRELY RDVAEVDTVR GVWLEEAGQK LLPSDMAVAL IDPATSARLT GPEFHEKLLS PYTGQSVSLF EQGLRLLDAQ KSHRVPLDVA SRALSAPRAD EPATYGELQQ SLLPLSEKAA LQARETFEKT GRTVTVWELI QELLRQFRTG LITIVEEVET LRAPVPASEL FEQLKDGKTT RTLLQGSGCL KVSIYEAMRR LLEAQAATGF YVHEAVKAGV SAEKAVTGYR FQAMQKGLVL QIATGGIIDP AYQRGYFSEE DTKGFFDPNT ERCVEDPETG KAEVVETTQV EETQIDIPGG WEVMQSDLIP EEQRAQLMAD MIIIIIEIIE ASYDYVRRRL ISLETYNLLR EAESAWCYLY PGSRQTLSIY EVARLLLEAQ KGERLTVDEA HDRLLSAERA QTISLFQAMK RLLDAQLATG LPLEVAYQRG SEPSEVRSYV TQLLRRCRRD SDARKLTFRG VRSQVMDEAT IEEVTKNLQK VFVDATKERL IRPGTAFELL DPIKGLKLTV PEFKDKLLSA YSGKLISLFQ HGIRLLEAQI SHRLPVEVAY EILTDPSDDT NLTYLQLMER LLPLKEKKRE KRRVVIVDPE YRKGLIDHQT WEEITISSSD RSGRQYDIDD ALDQYRAGTL GNAGGFRSRS ISPAVSRTQL GPVAGILDTE MHRNLVDNIT TGGIIDPSTG KGLVDKIMVD GFEDPRTKTK WLYYEAGQRF IEPDTPGRVP DARTAQKLRD PKTKLKISYK GTGLRLLEAA YSVSGSGSTA RAGSRRGSFD SSSSYSSSGY SLGGPESAVA FQAGRVTKER KTEIIRQQGL TAEDLFEARI EGTRSLREAL GTGSVAGVYL QALKKGLLSA AATGFLLDPV VRKGLVGPEL VTGYRDPYTE KELIPTEEAL GIVDPRLGFH YLNKDTHDQL DPSTDERLSY DGTGQLLLPL LRKQITMEEL ALQLREGLTS FLEGTSCIAG SVYQAMKKGI EAQAATGYVI EEAVRMGIVG ERAVTGYKDP AMKKGLILKD ATGGIIDPEE KRGLFDEEMN KGFFDPNTEE CITDPQTGLC RKTSSKSSVR TGKEMSVYEA YLELSEQECE GWKSMIIDR AIAKNLIDRS SITEFADMLS SSVGSSSSYP ASWSDPTEET TLEKVSITEA GQRLLEAQAC ERFPVTDAVN RINLAQKAFC MSAAQALKKG LEVQYLTGGL LDEALQRGTV VGAYSKYLTC DALDRSMVEE AQSTKGYYSP GSRTGSRTGS ATGSGFSMTF GRRYASGSSA 70 PLEC 4 Q151494 Entry version224 (18 Sep. 2019)Sequence version 3 (14 Oct. 2008) MSQHQLRVPQ SEDNLYLAVL DRVQKKTFTK RHISDLYEDL EVLSGDSLPR QNVQIALDYL RNDDIADGNP ILHFQISDIQ KEKLLLWSQR DNFTSSWRDG KPLLIDMNKV PEGLGRKRTS RASEGKKDER WVNKHLIKAQ RDGHNLISLL EKGRMRFHKL RHRQVKLVNI KLTLGLIWTI VSGQSEDMTA MVEGYQGLRC RLFNAIIHRH YRQTNLENLD QAFSVAERDL VDVPQPDEKS AMPRVPDVQD WQEYRELVLL AFEERRFPSS FLKFKEMELP GIYQSLEGAV YHPLDVEKEW EKQLRSEFER LQMEAGLCEE SDVRLLAAGK DLDKADSMIR DGRHPQGEQM LVAIRTEYNL TQVAQVTLQS TLRYLQDLLA GAEWGVDLPS LHQSIEEFRA QLSPATRGAY YAKLLNSSKA FVAAATKELM GFDWSDRNTN LMRELELKEK RLLREDHPAR QTQWSWMLQL NAAYFQFFSD LQEALRRKYS EDLLQDAQDE LSGLAKRAKA HPMRGRLPLL TVHKGDECQL VLSSSGSEAA PNQEAQEAVT TLWHQLHVDM RDVQLIRSWS EQRQALHSLE QDAGGFGPED CSHHYQQLLQ RCQRCISELK TRTVHRLRLP QRIAEQQKAQ ARLSAEAEKV PTLRSELELT SAIYLEKLKT AEEVLRAHEE TLPELEATKA AQQPTFDALR ERLQQRHGER VAQLLERWQA ELEQLGRQLR AWLQDARRRQ SQAVREQLRQ HGEKVEECQR DYELQLVTYK KKPKVQSGSE THYSELTTLT LRRMEEEERL RLAEVEAALE QAKAQAEREA VVRREEAAVD GVTRLLDPED IITYVSSLYD GVRANELQLR LLQWMRHHTA FEEIEILWSQ AKEADKNRSK QAGQLKVPPG GKLHVAILER LECLQRIVTK QLNQADALLQ VPQRAGEVER LLFNDVQTLK YRRVYRLHER RLKAGVAAPA VQRRPELEDS WVEENQHRVD VEAQLGSHRG KIERARSDEG RDCLGRLDLQ RLRSLESLHS WLNEKEEEEV MTAKKESYSA KIKELQNAGD PTVESFQAAL CCCIEAHLKE VREAEGQLQK CDRSATVTRL KEQLNEYKGH VVQLKPRHPA AVCDYKQVEV VGPAQPSHWK VPSVCFLVPP RLEAQHQALV KSLLAWQSLR LATFRTLKPE LHYQAFLRDS RLMAEREYGS SLEQGAQEES DIRLQLEACE LDKEPARECA AEVEGLGKGV LALPEPSPAA LGKLEQVRSL ISLVIRGTQG QLKEAQAVPA SLKKLRAQAE DELRGAQEVG DVEVERWRER VLAQTDVRQR YYRESADPLG EQIQAMPLAD EQALLEEIER FAKQYINAIK AQLEPVASPA SVIQEYVDLR SQYIKFISET AEQQRAEERE KQRQLAEAHA KELQQRMQEE AQQQKRSIQE ELQQLRQSSE EAAERSRLRI LEATERQRGG RAEEAEAQKR RQVQDESQRK VKAEAEAARE LRLQAEEAER RQVQVALETA KRASFAEKTA VAVAQLREEA ERAREEAERE ALRLRLQAEE EAEKQKEEAE EQAVRQRELA AEGTAQQRLA ETEQGEQQRQ REAAAATQKR RAEMEVLLAS TSEKSKQRLE EEAARLRALA EEDAARQRAE AIGEATRLKT AENERLRRLA EEQAAQHKAD ASDSELERQK RQVEEEILAL KAELELELGR SKEQAELEAA RRRREAEERV ARQRKAALEE ARRLRERAEQ EAAQKRLQAE KEQELQQTLQ GEAEAARRAA EREAAQSRRQ AEEQAQARAQ EAEQEAARRA QAADAEMEKH KAQVEQELTT QKNLLDEELQ RQRSQVEEEL SKLKARIEAE NTQRFLQEEA ARLSVAAQEA LAQQRALAEK EATRLKAEAE EQARRLQEDK TQGFQRTLEA EAERLKLRVA EDAQRFRKQA ELATQEKVTL SDHDAERLRE KLQQEAKLLQ QEQLLQETQA SLLQRERFIE QDEVAKAQQL MEQERQRLVA EAEEGVRRKQ RQQEELLAEE LEEQHRAALA AEIQAKARQA EEEIRVVRLQ AEGELQALRA QAQEEAERLR RQAEVELASR KQRALQALEE RLRQAEVERA QRSAEAELQS QLERSLQEEH ERRAQQQAEA LERWQLKANE VAQQKSLAQA REARRRGKAE EQELEKQRQL AEQELIRLRA LLEEELARLQ QELEAELAKV KARAEEESRS AEAGRFRELA EEAKRQRQLA AERVLAEKLA EAEIALKEKE EDEAFQRRRL IEERLAQLRK GLVEDTLRQR KASFEKAAAG IRSNAEDTLR RQRQLAAEEE QKSLAAEEEA VERLKAKVEE ESARQLQLAQ EKAHAFAVQQ QEQSVLDQLR EEAEEARVQA VEEAERLKQS AQAAAEKLRK QAEQAALRQK KKFAEQTLRQ LRLQLEETDH RLKAEATEAA FSVRVQMEEL NRALILRDKD EKMKQVAEEA ARLRQLAEED MLKEKMQAVQ LLQQQKELAQ EQMAQQLAEE ERQRQLEMSA EMSRAQARAE EEIGEKLHRT VQTLEIQRQQ AIAELEREKE LKSEEMQTVQ LQQSFLSEKD QEKAKLEQLF REEQQRQQQQ SMEEARRRQH EELQQLEQQR NQRLREQLQL HSEEVTASQV AATKTLPNGR EPEHSFDGLR AGILSAEELQ ELARREDVRH LLLKATNEKL LSPGTALILL DPVRNRRLTV PELHHKLLSA YTGQQISLFQ HGIRLLEAQI SHRVPVDVAY RVLADPSDDT NLTYLQLLER LLPLTDKAAK ARDVFEKATV TVTIWEIINS LLRQFRTGRI TVVEEQEQKG VPAAELLESR QRGERSVRDV RGANVIAGVW YNALKKDLLP QAGTGHIIDP AVRAGLVGPE AVTGYRDPYT KKGLIPREQG GGIVDPSKSH GCLDEETSRA YSDPSTGEPA PDQLTGLSLL QEELYSELQA VPVGGFKGRT YFTAEQRQEL VEKVIKILIT ERLSFSGLRA GVLSRAQFEQ LSELGSVRTL YLEDTKEKVS RATTAALLLE PVRNQRLYVH ELHEQLLSAE SGSTISLFQA GIRLLEAQIA HRVPVDVAYQ VLADPSDDTK LTYRQLLERC LPLKGAEKAE EETRRAFEET GGSTMSLWEV RAQLMADFQA IIIEIIEKTE DYVRRRLTAE ETYNLLREGT SAWCYLYGTG RQTLSIYQAL RLLLEAQAAT RLTVDEAVRK LLSAERAVTG SLFQAMKKEL DAQLATGGIV DALDGPAAEA RKVSAQRLQE RLAQGHTTVD YLQGRSSIAG SVYAALQRQL EAQAASGFLL NEAVKEGVVG ERAVTGYKDP AMQKGLIVRE ATGGVIDPVH RRGYFDEEMN KGFFDPNTHE CVEDPETGLC GGELVYTDSE SAPFGKFQGK EYFTAEQRRD TVEKIIKIII RLCFEGLRSL VIDRELYQQL AEVDTVRRAL LEEAGQKLSI SDMAVALLEA ATSARLTVDE FHEKLLSAEK GQSVSLFQAL LRLLDAQLST RVPLDVACAR LSAPRADAKA TYGELQQRCR PLSEKAARAR RETFEKTPVE VTVWELISSE LRQFRTGKVT IVEEVETLRQ PVPASELLAS LKDGKTTVKD LQGSGCLAGI IYEAMRRGLL AQAATGFLVD EAVKAGWGP KAVTGYRDPY MQKGLVLRQH TGGIIDPVHS RGYFSEEMNR GFFDPNTHEN VEDPETGLRL VVETTQVYTE QIDIPGGGSH MQSDLIPEEQ GRVTKERMII IIRQQGLASY DLFEARIISL RSLREALEAE SVAGVYLPGS KKGLLSAEVA GFLLDPVKGE GLVGPELHDR YRDPYTEQTI IPTEEALRLL DPRLGFHLPL EVAYQRGYLN SEVRSYVDPS LRRCRRDDGT RKLTFRGLRK QVMDEATALQ VTKNLQKFLE DATKERLSVY GTAFELLEAQ KGLKLTVEEA KDKLLSAERA KLISLFQAMK RLLEAQIATG LPVEVAYKRG TDPSDDTKGF YLQLMERCIT LKEKKRERKT WIVDPETGK GLIDHQTYLE ITISSSDGVV RQYDIDDAIA QYRAGTLSIT GGFRSRSSSV AVSRTQLASW AGILDTETLE NLVDNITGQR IIDPSTGERF VDKIMVDRIN DPRTKTKMSA YEAGQRFLEV DTPGRVPLDE TAQKLRDVGA KLKISYKDAL LRLLEAAAQS SGSGSTAGSR SRRGSFDATG SYSSSGYGRR GPESAVA KDTHDQLSEP TDERLSYTQL GQLLLPLSDA QITMEELVRS LREGLTSIEE GTSCIAGVFV QAMKKGIIRP AATGYVIDPI VRMGIVGPEF VTGYKDPYSG KGLILKDHGI GIIDPEESHR LFDEEMNEIL FDPNTEENLT DPQTGLCLLP SSKSSVRKRR EMSVYEAYRK LSEQECEWEE KSMIIDRRSG KNLIDRSALD EFADMLSGNA GSSSSYPISP SDPTEETGPV KVSITEAMHR LLEAQACTGG PVTDAVNKGL LAQKAFCGFE AQALKKGWLY QYLTGGLIEP ALQRGTVDAR YSKYLTCPKT DRSMVEEGTG TKGYYSPYSV TGSRTGSRAG SGFSMTFSSS YASGSSASLG 71 PLEC 5 Q151495 Entry version 224 (18 Sep. 2019) Sequence version 3 (14 Oct. 2008) MEPSGSLFPS AAVWHWRRGR DRVQKKTFTK RHISDLYEDL EVLSGDSLPR QNVQIALDYL RNDDIADGNP ILHFQISDIQ KEKLLLWSQR DNFTSSWRDG KPLLIDMNKV QAFSVAERDL VDVPQPDEKS AMPRVPDVQD WQEYRELVLL AFEERRFPSS FLKFKEMELP GIYQSLEGAV YHPLDVEKEW EKQLRSEFER LQMEAGLCEE SDVRLLAAGK LVVVGHVVTL RWAQDEQDER WVNKHLIKAQ RDGHNLISLL EKGRMRFHKL RHRQVKLVNI KLTLGLIWTI VSGQSEDMTA MVEGYQGLRC RLFNAIIHRH YRQTNLENLD GVTRLLDPED IITYVSSLYD GVRANELQLR LLQWMRHHTA FEEIEILWSQ AKEADKNRSK QAGQLKVPPG GKLHVAILER LECLQRIVTK QLNQADALLQ VPQRAGEVER DLDKADSMIR DGRHPQGEQM LVAIRTEYNL TQVAQVTLQS TLRYLQDLLA GAEWGVDLPS LHQSIEEFRA QLSPATRGAY YAKLLNSSKA WLNEKEEEEV GFDWSDRNTN LMRELELKEK RLLREDHPAR QTQWSWMLQL NAAYFQFFSD LQEALRRKYS EDLLQDAQDE LSGLAKRAKA HPMRGRLPLL TVHKGDECQL VLSSSGSEAA PNQEAQEAVT TLWHQLHVDM RDVQLIRSWS EQRQALHSLE QDAGGFGPED CSHHYQQLLQ RCQRCISELK TRTVHRLRLP QRIAEQQKAQ ARLSAEAEKV PTLRSELELT SAIYLEKLKT AEEVLRAHEE TLPELEATKA AQQPTFDALR ERLQQRHGER VAQLLERWQA ELEQLGRQLR AWLQDARRRQ SQAVREQLRQ HGEKVEECQR DYELQLVTYK KKPKVQSGSE THYSELTTLT LRRMEEEERL RLAEVEAALE QAKAQAEREA VVRREEAAVD ELQQLRQSSE EAAERSRLRI LEATERQRGG RAEEAEAQKR RQVQDESQRK VKAEAEAARE LRLQAEEAER RQVQVALETA KRASFAEKTA VAVAQLREEA ERAREEAERE LLFNDVQTLK YRRVYRLHER RLKAGVAAPA VQRRPELEDS WVEENQHRVD VEAQLGSHRG KIERARSDEG RDCLGRLDLQ RLRSLESLHS FVAAATKELM MTAKKESYSA KIKELQNAGD PTVESFQAAL CCCIEAHLKE VREAEGQLQK CDRSATVTRL KEQLNEYKGH VVQLKPRHPA AVCDYKQVEV VGPAQPSHWK VPSVCFLVPP RLEAQHQALV KSLLAWQSLR LATFRTLKPE LHYQAFLRDS RLMAEREYGS SLEQGAQEES DIRLQLEACE LDKEPARECA AEVEGLGKGV LALPEPSPAA LGKLEQVRSL ISLVIRGTQG QLKEAQAVPA SLKKLRAQAE DELRGAQEVG DVEVERWRER VLAQTDVRQR YYRESADPLG EQIQAMPLAD EQALLEEIER FAKQYINAIK AQLEPVASPA SVIQEYVDLR SQYIKFISET AEQQRAEERE KQRQLAEAHA KELQQRMQEE AQQQKRSIQE AEIQAKARQA EEEIRVVRLQ AEGELQALRA QAQEEAERLR RQAEVELASR KQRALQALEE RLRQAEVERA QRSAEAELQS QLERSLQEEH ERRAQQQAEA LERWQLKANE ALRLRLQAEE EAEKQKEEAE EQAVRQRELA AEGTAQQRLA ETEQGEQQRQ REAAAATQKR RAEMEVLLAS TSEKSKQRLE EEAARLRALA EEDAARQRAE AIGEATRLKT AENERLRRLA EEQAAQHKAD ASDSELERQK RQVEEEILAL KAELELELGR SKEQAELEAA RRRREAEERV ARQRKAALEE ARRLRERAEQ EAAQKRLQAE KEQELQQTLQ GEAEAARRAA EREAAQSRRQ AEEQAQARAQ EAEQEAARRA QAADAEMEKH KAQVEQELTT QKNLLDEELQ RQRSQVEEEL SKLKARIEAE NTQRFLQEEA ARLSVAAQEA LAQQRALAEK EATRLKAEAE EQARRLQEDK TQGFQRTLEA EAERLKLRVA EDAQRFRKQA ELATQEKVTL SDHDAERLRE KLQQEAKLLQ QEQLLQETQA SLLQRERFIE QDEVAKAQQL MEQERQRLVA EAEEGVRRKQ RQQEELLAEE LEEQHRAALA AATKTLPNGR EPEHSFDGLR AGILSAEELQ ELARREDVRH LLLKATNEKL LSPGTALILL DPVRNRRLTV PELHHKLLSA YTGQQISLFQ HGIRLLEAQI SHRVPVDVAY VAQQKSLAQA REARRRGKAE EQELEKQRQL AEQELIRLRA LLEEELARLQ QELEAELAKV KARAEEESRS AEAGRFRELA EEAKRQRQLA AERVLAEKLA EAEIALKEKE EDEAFQRRRL IEERLAQLRK GLVEDTLRQR KASFEKAAAG IRSNAEDTLR RQRQLAAEEE QKSLAAEEEA VERLKAKVEE ESARQLQLAQ EKAHAFAVQQ QEQSVLDQLR EEAEEARVQA VEEAERLKQS AQAAAEKLRK QAEQAALRQK KKFAEQTLRQ LRLQLEETDH RLKAEATEAA FSVRVQMEEL NRALILRDKD EKMKQVAEEA ARLRQLAEED MLKEKMQAVQ LLQQQKELAQ EQMAQQLAEE ERQRQLEMSA EMSRAQARAE EEIGEKLHRT VQTLEIQRQQ AIAELEREKE LKSEEMQTVQ LQQSFLSEKD QEKAKLEQLF REEQQRQQQQ SMEEARRRQH EELQQLEQQR NQRLREQLQL HSEEVTASQV DALDGPAAEA RKVSAQRLQE RLAQGHTTVD YLQGRSSIAG SVYAALQRQL EAQAASGFLL NEAVKEGVVG ERAVTGYKDP AMQKGLIVRE ATGGVIDPVH RRGYFDEEMN RVLADPSDDT NLTYLQLLER LLPLTDKAAK ARDVFEKATV TVTIWEIINS LLRQFRTGRI TVVEEQEQKG VPAAELLESR QRGERSVRDV RGANVIAGVW YNALKKDLLP QAGTGHIIDP AVRAGLVGPE AVTGYRDPYT KKGLIPREQG GGIVDPSKSH GCLDEETSRA YSDPSTGEPA PDQLTGLSLL QEELYSELQA VPVGGFKGRT YFTAEQRQEL VEKVIKILIT ERLSFSGLRA GVLSRAQFEQ LSELGSVRTL YLEDTKEKVS RATTAALLLE PVRNQRLYVH ELHEQLLSAE SGSTISLFQA GIRLLEAQIA HRVPVDVAYQ VLADPSDDTK LTYRQLLERC LPLKGAEKAE EETRRAFEET GGSTMSLWEV RAQLMADFQA IIIEIIEKTE DYVRRRLTAE ETYNLLREGT SAWCYLYGTG RQTLSIYQAL RLLLEAQAAT RLTVDEAVRK LLSAERAVTG SLFQAMKKEL DAQLATGGIV EVAYQRGYLN SEVRSYVDPS LRRCRRDDGT RKLTFRGLRK QVMDEATALQ VTKNLQKFLE DATKERLSVY GTAFELLEAQ KGLKLTVEEA KDKLLSAERA KLISLFQAMK KGFFDPNTHE CVEDPETGLC GGELVYTDSE SAPFGKFQGK EYFTAEQRRD TVEKIIKIII RLCFEGLRSL VIDRELYQQL AEVDTVRRAL LEEAGQKLSI SDMAVALLEA ATSARLTVDE FHEKLLSAEK GQSVSLFQAL LRLLDAQLST RVPLDVACAR LSAPRADAKA TYGELQQRCR PLSEKAARAR RETFEKTPVE VTVWELISSE LRQFRTGKVT IVEEVETLRQ PVPASELLAS LKDGKTTVKD LQGSGCLAGI IYEAMRRGLL AQAATGFLVD EAVKAGWGP KAVTGYRDPY MQKGLVLRQH TGGIIDPVHS RGYFSEEMNR GFFDPNTHEN VEDPETGLRL WETTQVYTE QIDIPGGGSH MQSDLIPEEQ GRVTKERMII IIRQQGLASY DLFEARIISL RSLREALEAE SVAGVYLPGS KKGLLSAEVA GFLLDPVKGE GLVGPELHDR YRDPYTEQTI IPTEEALRLL DPRLGFHLPL KDTHDQLSEP TDERLSYTQL GQLLLPLSDA QITMEELVRS LREGLTSIEE GTSCIAGVFV QAMKKGIIRP AATGYVIDPI VRMGIVGPEF VTGYKDPYSG KGLILKDHGI RLLEAQIATG LPVEVAYKRG TDPSDDTKGF YLQLMERCIT LKEKKRERKT WIVDPETGK GLIDHQTYLE ITISSSDGVV RQYDIDDAIA QYRAGTLSIT GGFRSRSSSV AVSRTQLASW AGILDTETLE NLVDNITGQR IIDPSTGERF VDKIMVDRIN DPRTKTKMSA YEAGQRFLEV DTPGRVPLDE TAQKLRDVGA KLKISYKDAL LRLLEAAAQS SGSGSTAGSR SRRGSFDATG SYSSSGYGRR GPESAVA GIIDPEESHR LFDEEMNEIL FDPNTEENLT DPQTGLCLLP SSKSSVRKRR EMSVYEAYRK LSEQECEWEE KSMIIDRRSG KNLIDRSALD EFADMLSGNA GSSSSYPISP SDPTEETGPV KVSITEAMHR LLEAQACTGG PVTDAVNKGL LAQKAFCGFE AQALKKGWLY QYLTGGLIEP ALQRGTVDAR YSKYLTCPKT DRSMVEEGTG TKGYYSPYSV TGSRTGSRAG SGFSMTFSSS YASGSSASLG 72 PLEC 6 Q151496 Entry version 224 (18 Sep. 2019) Sequence version 3 (14 Oct. 2008) MSGAGGAFAS WLDGGCEPAR VDERDRVQKK IKAQRHISDL ISLLEVLSGD FHKLQNVQIA LVNIRNDDIA IWTIILHFQI DMTAKEKLLL GLRCDNFTSS IHRHKPLLID ENLDQAFSVA DPEDVDVPQP SLYDAMPRVP LQLRWQEYRE HHTAAFEERR LWSQFLKFKE NRSKGIYQSL VPPGYHPLDV ILEREKQLRS IVTKLQMEAG ALLQSDVRLL EVERDLDKAD QTLKDGRHPQ LHERLVAIRT AAPATQVAQV LEDSTLRYLQ HRVDGAEWGV SHRGLHQSIE SDEGQLSPAT LDLQYAKLLN SLHSFVAAAT EEEVGFDWSD PREVLLERPC RGYLYQQLCC TFTKWVNKHL YEDLRDGHNL SLPREKGRMR LDYLRHRQVK DGNPKLTLGL SDIQVSGQSE WSQRMVEGYQ WRDGRLFNAI MNKVYRQTNL ERDLGVTRLL DEKSIITYVS DVQDGVRANE LVLLLLQWMR FPSSFEEIEI MELPAKEADK EGAVQAGQLK EKEWGKLHVA EFERLECLQR LCEEQLNQAD AAGKVPQRAG SMIRLLFNDV GEQMYRRVYR EYNLRLKAGV TLQSVQRRPE DLLAWVEENQ DLPSVEAQLG EFRAKIERAR RGAYRDCLGR SSKARLRSLE KELMWLNEKE RNTNMTAKKE SYSALMRELE NAGDRLLRED QAALQTQWSW HLKENAAYFQ QLQKLQEALR VTRLEDLLQD YKGHLSGLAK RHPAHPMRGR QVEVTVHKGD SHWKVLSSSG LVPPPNQEAQ QALVTLWHQL QSLRRDVQLI LKPEEQRQAL LRDSQDAGGF EYGSCSHHYQ QEESRCQRCI EACETRTVHR RECAQRIAEQ GKGVARLSAE SPAAPTLRSE VRSLSAIYLE GTQGAEEVLR AVPATLPELE AQAEAQQPTF QEVGERLQQR HGERDVEVER VRQRELEQLG DPLGAWLQDA PLADSQAVRE EIERHGEKVE NAIKDYELQL ASPAKKPKVQ VDLRTHYSEL ISETLRRMEE EERERLAEVE EAHAQAKAQA MQEEWRREE SIQEELQQLR ARQAEAAERS VRLQLEATER ALRARAEEAE ERLRRQVQDE LASRVKAEAE ALEELRLQAE VERARQVQVA ELQSKRASFA QEEHVAVAQL QAEAERAREE KANEALRLRL LAQAEAEKQK GKAEEQAVRQ QRQLAEGTAQ RLRAETEQGE ARLQREAAAA LAKVRAEMEV ESRSTSEKSK RELAEEAARL RQLAEEDAAR EKLAAIGEAT LKEKKIKELQ HPARPTVESF MLQLCCCIEA FFSDVREAEG RKYSCDRSAT AQDEKEQLNE RAKAVVQLKP LPLLAVCDYK ECQLVGPAQP SEAAVPSVCF EAVTRLEAQH HVDMKSLLAW RSWSLATFRT HSLELHYQAF GPEDRLMAER QLLQSLEQGA SELKDIRLQL LRLPLDKEPA QKAQAEVEGL AEKVLALPEP LELTLGKLEQ KLKTISLVIR AHEEQLKEAQ ATKASLKKLR DALRDELRGA WRERVAQLLE RWQAVLAQTD RQLRYYRESA RRRQEQIQAM QLRQEQALLE ECQRFAKQYI VTYKAQLEPV SGSESVIQEY TTLTSQYIKF EERLAEQQRA AALEKQRQLA EREAKELQQR AAVDAQQQKR QSSEAEIQAK RLRIEEEIRV QRGGAEGELQ AQKRQAQEEA SQRKRQAEVE AAREKQRALQ EAERRLRQAE LETAQRSAEA EKTAQLERSL REEAERRAQQ AERELERWQL QAEEVAQQKS EEAEREARRR RELAEQELEK QRLAAEQELI QQRQLLEEEL TQKRQELEAE LLASKARAEE QRLEAEAGRF RALAEEAKRQ QRAEAERVLA RLKTEAEIAL KEKEAENERL RRRLEEQAAQ QLRKASDSEL LRQRRQVEEE AAAGKAELEL DTLRSKEQAE AEEERRRREA EEEAARQRKA KVEEARRLRE QLAQEAAQKR AVQQKEQELQ DQLRGEAEAA RVQAEREAAQ LKQSAEEQAQ KLRKEAEQEA LRQKQAADAE TLRQKAQVEQ ETDHQKNLLD TEAARQRSQV MEELSKLKAR RDKDNTQRFL AEEAARLSVA AEEDLAQQRA QAVQEATRLK ELAQEQARRL LAEETQGFQR EMSAEAERLK ARAEEDAQRF LHRTELATQE QRQQSDHDAE REKEKLQQEA QTVQQEQLLQ SEKDSLLQRE EQLFQDEVAK QQQQMEQERQ RRQHEAEEGV EQQRRQQEEL QLQLLEEQHR ASQVAATKTL AAEAEPEHSF RLQEAGILSA TTVDELARRE SIAGLLLKAT QRQLLSPGTA GFLLDPVRNR GVVGPELHHK YKDPYTGQQI IVREHGIRLL DPVHSHRVPV EEMNRVLADP NTHENLTYLQ TGLCLLPLTD TDSEARDVFE FQGKTVTIWE QRRDLLRQFR KIIITWEEQ LRSLVPAAEL YQQLQRGERS RRALRGANVI KLSIYNALKK RRLAEDEAFQ HKADIEERLA ERQKGLVEDT ILALKASFEK ELGRIRSNAE LEAARQRQLA EERVQKSLAA ALEEVERLKA RAEQESARQL LQAEEKAHAF QTLQQEQSVL RRAAEEAEEA SRRQVEEAER ARAQAQAAAE ARRAQAEQAA MEKHKKFAEQ ELTTLRLQLE EELQRLKAEA EEELFSVRVQ IEAENRALIL QEEAEKMKQV AQEAARLRQL LAEKMLKEKM AEAELLQQQK QEDKEQMAQQ TLEAERQRQL LRVAEMSRAQ RKQAEEIGEK KVTLVQTLEI RLREAIAELE KLLQLKSEEM ETQALQQSFL RFIEQEKAKL AQQLREEQQR RLVASMEEAR RRKQEELQQL LAEENQRLRE AALAHSEEVT PNGRDALDGP DGLRRKVSAQ EELQRLAQGH DVRHYLQGRS NEKLSVYAAL LILLEAQAAS RLTVNEAVKE LLSAERAVTG SLFQAMQKGL EAQIATGGVI DVAYRRGYFD SDDTKGFFDP LLERCVEDPE KAAKGGELVY KATVSAPFGK IINSEYFTAE TGRITVEKII EQKGRLCFEG LESRVIDREL VRDVAEVDTV AGVWLEEAGQ DLLPSDMAVA LLEAQAGTGH TVDEAVRAGL SAEKAVTGYR FQALKKGLIP QLSTGGIVDP ACARGCLDEE DAKAYSDPST QRCRPDQLTG ARARQEELYS TPVEVPVGGF ISSEYFTAEQ GKVTVEKVIK TLRQERLSFS LLASGVLSRA TVKDLSELGS LAGIYLEDTK RGLLRATTAA FLVDPVRNQR VVGPELHEQL RDPYSGSTIS LRQHGIRLLE PVHSHRVPVD EMNRVLADPS THENLTYRQL GLRLLPLKGA VYTEEETRRA GGSHGGSTMS PEEQRAQLMA RMIIIIIEII LASYDYVRRR IISLETYNLL LEAESAWCYL LPGSRQTLSI AEVARLLLEA VKGERLTVDE LHDRLLSAER EQTISLFQAM LRLLDAQLAT HLPLEVAYQR LSEPSEVRSY YTQLLRRCRR LSDARKLTFR LVRSQVMDEA SIEEVTKNLQ GVFVDATKER IIRPGTAFEL IDPIKGLKLT GPEFKDKLLS PYSGKLISLF DHGIRLLEAQ ESHRLPVEVA NEILTDPSDD ENLTYLQLME CLLPLKEKKR RKRRVVIVDP AYRKGLIDHQ EWEEITISSS RRSGRQYDID SALDQYRAGT SGNAGGFRSR IIDPATSARL VGPEFHEKLL DPYTGQSVSL REQGLRLLDA SKSHRVPLDV TSRALSAPRA GEPATYGELQ LSLLPLSEKA ELQARETFEK KGRTVTVWEL RQELLRQFRT ILITIVEEVE GLRAPVPASE QFEQLKDGKT VRTLLQGSGC EKVSIYEAMR LLLEAQAATG LYVHEAVKAG LSAEKAVTGY LFQAMQKGLV AQIATGGIID VAYQRGYFSE DDTKGFFDPN LERCVEDPET EKAEWETTQ FEETQIDIPG LWEVMQSDLI DFQAGRVTKE EKTEIIRQQG LTAEDLFEAR REGTRSLREA YGTGSVAGVY YQALKKGLLS QAATGFLLDP AVRKGLVGPE AVTGYRDPYT KKELIPTEEA GGIVDPRLGF GYLNKDTHDQ VDPSTDERLS DDGTGQLLLP GLRKQITMEE TALQLREGLT KFLEGTSCIA LSVYQAMKKG LEAQAATGYV VEEAVRMGIV AERAVTGYKD QAMKKGLILK IATGGIIDPE YKRGLFDEEM TKGFFDPNTE RCITDPQTGL ERKTSSKSSV ETGKEMSVYE TYLELSEQEC DGWKSMIID DAIAKNLIDR LSITEFADML SSSVGSSSSY PISPAVSRTQ TGPVAGILDT AMHRNLVDNI CTGGIIDPST NKGLVDKIMV CGFEDPRTKT GWLYYEAGQR LIEPDTPGRV VDARTAQKLR CPKTKLKISY EGTGLRLLEA PYSVSGSGST SRAGSRRGSF FSSSSYSSSG ASLGGPESAV LASWSDPTEE ETLEKVSITE TGQRLLEAQA GERFPVTDAV DRINLAQKAF KMSAAQALKK FLEVQYLTGG PLDEALQRGT DVGAYSKYLT KDALDRSMVE AAQSTKGYYS AGSRTGSRTG DATGSGFSMT YGRRYASGSS A 73 PLEC 7 Q151497 Entry version 224 (18 Sep. 2019) Sequence version 3 (14 Oct. 2008) MKIVPDERDR NKHLIKAQRH GHNLISLLEV GRMRFHKLQN RQVKLVNIRN TLGLIWTIIL GQSEDMTAKE EGYQGLRCDN FNAIIHRHKP QTNLENLDQA TRLLDPEDVD TYVSSLYDAM RANELQLRWQ QWMRHHTAAF EIEILWSQFL EADKNRSKGI GQLKVPPGYH LHVAILEREK CLQRIVTKLQ NQADALLQSD QRAGEVERDL FNDVQTLKDG RVYRLHERLV KAGVAAPATQ RRPELEDSTL EENQHRVDGA AQLGSHRGLH ERARSDEGQL CLGRLDLQYA RSLESLHSFV NEKEEEEVGF AKKESYSALM KELQNAGDRL VESFQAALQT CIEAHLKENA EAEGQLQKLQ RSATVTRLED QLNEYKGHLS QLKPRHPAHP CDYKQVEVTV PAQPSHWKVL SVCFLVPPPN EAQHQALVTL LLAWQSLRRD VQKKTFTKWV ISDLYEDLRD LSGDSLPREK VQIALDYLRH DDIADGNPKL HFQISDIQVS KLLLWSQRMV FTSSWRDGRL LLIDMNKVYR FSVAERDLGV VPQPDEKSII PRVPDVQDGV EYRELVLLLL EERRFPSSFE KFKEMELPAK YQSLEGAVQA PLDVEKEWGK QLRSEFERLE MEAGLCEEQL VRLLAAGKVP DKADSMIRLL RHPQGEQMYR AIRTEYNLRL VAQVTLQSVQ RYLQDLLAWV EWGVDLPSVE QSIEEFRAKI SPATRGAYRD KLLNSSKARL AAATKELMWL DWSDRNTNMT RELELKEKKI LREDHPARPT QWSWMLQLCC AYFQFFSDVR EALRRKYSCD LLQDAQDEKE CLAKRAKAVV MRGRLPLLAV HKGDECQLVG SSSGSEAAVP QEAQEAVTRL WHQLHVDMKS VQLIRSWSLA TFRTLKPEEQ YQAFLRDSQD MAEREYGSCS EQGAQEESRC RLQLEACETR KEPARECAQR VEGLGKGVAR LPEPSPAAPT KLEQVRSLSA LVIRGTQGAE KEAQAVPATL KKLRAQAEAQ LRGAQEVGER EVERWRERVA AQTDVRQREL RESADPLGAW IQAMPLADSQ ALLEEIERHG KQYINAIKDY LEPVASPAKK IQEYVDLRTH YIKFISETLR QQRAEERERL RQLAEAHAQA LQQRMQEEW QQKRSIQEEL IQAKARQAEA EIRVVRLQLE GELQALRARA QEEAERLRRQ AEVELASRVK RALQALEELR RQAEVERARQ SAEAELQSKR ERSLQEEHVA RAQQQAEAER RWQLKANEAL QQKSLAQAEA ARRRGKAEEQ ELEKQRQLAE QELIRLRAET EEELARLQRE LEAELAKVRA RAEEESRSTS AGRFRELAEE AKRQRQLAEE RVLAEKLAAI EIALKEKEAE EAFQRRRLEE ERLAQLRKAS VEDTLRQRRQ SFEKAAAGKA SNAEDTLRSK RQLAAEEERR SLAAEEEAAR RLKAKVEEAR ARQLQLAQEA AHAFAVQQKE QSVLDQLRGE AEEARVQAER RQALHSLELH AGGFGPEDRL HHYQQLLQSL QRCISELKDI TVHRLRLPLD IAEQQKAQAE LSAEAEKVLA LRSELELTLG IYLEKLKTIS EVLRAHEEQL PELEATKASL QPTFDALRDE LQQRHGERDV QLLERWQAVL EQLGRQLRYY LQDARRRQEQ AVREQLRQEQ EKVEECQRFA ELQLVTYKAQ PKVQSGSESV YSELTTLTSQ RMEEEERLAE AEVEAALEKQ KAQAEREAKE RREEAAVDAQ QQLRQSSEAE AERSRLRIEE ATERQRGGAE EEAEAQKRQA VQDESQRKRQ AEAEAAREKQ LQAEEAERRL VQVALETAQR ASFAEKTAQL VAQLREEAER AREEAERELE RLRLQAEEVA EKQKEEAERE AVRQRELAEQ GTAQQRLAAE EQGEQQRQLL AAAATQKRQE EMEVLLASKA EKSKQRLEAE AARLRALAEE DAARQRAEAE GEATRLKTEA NERLRRLAED QAAQHKADIE DSELERQKGL VEEEILALKA ELELELGRIR EQAELEAARQ RREAEERVQK QRKAALEEVE RLRERAEQES AQKRLQAEEK QELQQTLQQE AEAARRAAEE EAAQSRRQVE EAERLKQSAE AAAEKLRKEA EQAALRQKQA FAEQTLRQKA LQLEETDHQK KAEATEAARQ VRVQMEELSK ALILRDKDNT MKQVAEEAAR LRQLAEEDLA KEKMQAVQEA QQQKELAQEQ MAQQLAEETQ QRQLEMSAEA SRAQARAEED IGEKLHRTEL TLEIQRQQSD AELEREKEKL SEEMQTVQQE QSFLSEKDSL KAKLEQLFQD EQQRQQQQME EEARRRQHEA LQQLEQQRRQ RLREQLQLLE EEVTASQVAA LDGPAAEAEP VSAQRLQEAG AQGHTTVDEL QGRSSIAGLL YAALQRQLLS QAASGFLLDP AVKEGVVGPE AVTGYKDPYT QKGLIVREHG GGVIDPVHSH GYFDEEMNRV FFDPNTHENL EDPETGLCLL ELVYTDSEAR PFGKFQGKTV FTAEQRRDLL EKIIKIIITV CFEGLRSLVP DRELYQQLQR VDTVRRALRG EAGQKLSIYN MAVALLEAQA SARLTVDEAV EKLLSAEKAV SVSLFQALKK LLDAQLSTGG PLDVACARGC APRADAKAYS GELQQRCRPD SEKAARARQE TFEKTPVEVP VWELISSEYF QFRTGKVTVE EEVETLRQER EQAQARAQAQ EQEAARRAQA ADAEMEKHKK QVEQELTTLR NLLDEELQRL RSQVEEELFS LKARIEAENR QRFLQEEAEK LSVAAQEAAR QQRALAEKML TRLKAEAELL ARRLQEDKEQ GFQRTLEAER ERLKLRVAEM AQRFRKQAEE ATQEKVTLVQ HDAERLREAI QQEAKLLQLK QLLQETQALQ LQRERFIEQE EVAKAQQLRE QERQRLVASM EEGVRRKQEE QEELLAEENQ EQHRAALAHS TKTLPNGRDA EHSFDGLRRK ILSAEELQRL ARREDVRHYL LKATNEKLSV PGTALILLEA VRNRRLTVNE LHHKLLSAER GQQISLFQAM IRLLEAQIAT RVPVDVAYRR LADPSDDTKG TYLQLLERCV PLTDKAAKGG DVFEKATVSA TIWEIINSEY RQFRTGRITV VEEQEQKGRL AAELLESRVI GERSVRDVAE ANVIAGVWLE ALKKDLLPSD GTGHIIDPAT RAGLVGPEFH TGYRDPYTGQ GLIPREQGLR IVDPSKSHRV LDEETSRALS DPSTGEPATY QLTGLSLLPL ELYSELQARE VGGFKGRTVT TAEQRQELLR KVIKILITIV LSFSGLRAPV PASELLASGV DGKTTVKDLS GSGCLAGIYL EAMRRGLLRA AATGFLVDPV VKAGVVGPEL VTGYRDPYSG KGLVLRQHGI GIIDPVHSHR YFSEEMNRVL FDPNTHENLT DPETGLRLLP ETTQVYTEEE DIPGGGSHGG SDLIPEEQRA VTKERMIIII RQQGLASYDY FEARIISLET LREALEAESA AGVYLPGSRQ GLLSAEVARL LLDPVKGERL VGPELHDRLL DPYTEQTISL TEEALRLLDA RLGFHLPLEV THDQLSEPSE ERLSYTQLLR LLLPLSDARK TMEELVRSQV EGLTSIEEVT SCIAGVFVDA MKKGIIRPGT TGYVIDPIKG MGIVGPEFKD GYKDPYSGKL LILKDHGIRL IDPEESHRLP DEEMNEILTD PNTEENLTYL QTGLCLLPLK KSSVRKRRVV SVYEAYRKGL EQECEWEEIT MIIDRRSGRQ LIDRSALDQY ADMLSGNAGG SSSYPISPAV PTEETGPVAG SITEAMHRNL EAQACTGGII TDAVNKGLVD QKAFCGFEDP ALKKGWLYYE LTGGLIEPDT QRGTVDARTA KYLTCPKTKL SMVEEGTGLR GYYSPYSVSG SRTGSRAGSR LSRAQFEQLK ELGSVRTLLQ EDTKEKVSIY TTAALLLEAQ RNQRLYVHEA HEQLLSAEKA STISLFQAMQ RLLEAQIATG VPVDVAYQRG ADPSDDTKGF YRQLLERCVE LKGAEKAEW TRRAFEETQI STMSLWEVMQ QLMADFQAGR IEIIEKTEII VRRRLTAEDL YNLLREGTRS WCYLYGTGSV TLSIYQALKK LLEAQAATGF TVDEAVRKGL SAERAVTGYR FQAMKKELIP QLATGGIVDP AYQRGYLNKD VRSYVDPSTD RCRRDDGTGQ LTFRGLRKQI MDEATALQLR KNLQKFLEGT TKERLSVYQA AFELLEAQAA LKLTVEEAVR KLLSAERAVT ISLFQAMKKG LEAQIATGGI VEVAYKRGLF PSDDTKGFFD QLMERCITDP EKKRERKTSS IVDPETGKEM IDHQTYLELS ISSSDGVVKS YDIDDAIAKN RAGTLSITEF FRSRSSSVGS SRTQLASWSD ILDTETLEKV VDNITGQRLL DPSTGERFPV KIMVDRINLA RTKTKMSAAQ AGQRFLEVQY PGRVPLDEAL QKLRDVGAYS KISYKDALDR LLEAAAQSTK SGSTAGSRTG RGSFDATGSG FSMTFSSSSY SGSSASLGGP SSSGYGRRYA ESAVA 74 PLEC 8 Q151498 Entry version 224 (18 Sep. 2019) Sequence version 3 (14 Oct. 2008) MDPSRAIQNE VQKKTFTKWV ISDLYEDLRD LSGDSLPREK VQIALDYLRH DDIADGNPKL HFQISDIQVS KLLLWSQRMV FTSSWRDGRL LLIDMNKVYR FSVAERDLGV VPQPDEKSII PRVPDVQDGV EYRELVLLLL EERRFPSSFE KFKEMELPAK YQSLEGAVQA PLDVEKEWGK QLRSEFERLE MEAGLCEEQL VRLLAAGKVP DKADSMIRLL RHPQGEQMYR AIRTEYNLRL VAQVTLQSVQ RYLQDLLAWV EWGVDLPSVE QSIEEFRAKI SPATRGAYRD KLLNSSKARL AAATKELMWL DWSDRNTNMT RELELKEKKI LREDHPARPT QWSWMLQLCC AYFQFFSDVR EALRRKYSCD LLQDAQDEKE CLAKRAKAVV MRGRLPLLAV HKGDECQLVG SSSGSEAAVP QEAQEAVTRL WHQLHVDMKS VQLIRSWSLA RQALHSLELH AGGFGPEDRL HHYQQLLQSL QRCISELKDI TVHRLRLPLD IAEQQKAQAE LSAEAEKVLA LRSELELTLG IYLEKLKTIS EVLRAHEEQL PELEATKASL QPTFDALRDE ISSLKDERDR NKHLIKAQRH GHNLISLLEV GRMRFHKLQN RQVKLVNIRN TLGLIWTIIL GQSEDMTAKE EGYQGLRCDN FNAIIHRHKP QTNLENLDQA TRLLDPEDVD TYVSSLYDAM RANELQLRWQ QWMRHHTAAF EIEILWSQFL EADKNRSKGI GQLKVPPGYH LHVAILEREK CLQRIVTKLQ NQADALLQSD QRAGEVERDL FNDVQTLKDG RVYRLHERLV KAGVAAPATQ RRPELEDSTL EENQHRVDGA AQLGSHRGLH ERARSDEGQL CLGRLDLQYA RSLESLHSFV NEKEEEEVGF AKKESYSALM KELQNAGDRL VESFQAALQT CIEAHLKENA EAEGQLQKLQ RSATVTRLED QLNEYKGHLS QLKPRHPAHP CDYKQVEVTV PAQPSHWKVL SVCFLVPPPN EAQHQALVTL LLAWQSLRRD TFRTLKPEEQ YQAFLRDSQD MAEREYGSCS EQGAQEESRC RLQLEACETR KEPARECAQR VEGLGKGVAR LPEPSPAAPT KLEQVRSLSA LVIRGTQGAE KEAQAVPATL KKLRAQAEAQ LRGAQEVGER LQQRHGERDV QLLERWQAVL EQLGRQLRYY LQDARRRQEQ AVREQLRQEQ EKVEECQRFA ELQLVTYKAQ PKVQSGSESV YSELTTLTSQ RMEEEERLAE AEVEAALEKQ KAQAEREAKE RREEAAVDAQ QQLRQSSEAE AERSRLRIEE ATERQRGGAE EEAEAQKRQA VQDESQRKRQ AEAEAAREKQ LQAEEAERRL VQVALETAQR ASFAEKTAQL VAQLREEAER AREEAERELE RLRLQAEEVA EKQKEEAERE AVRQRELAEQ GTAQQRLAAE EQGEQQRQLL AAAATQKRQE EMEVLLASKA EKSKQRLEAE AARLRALAEE DAARQRAEAE GEATRLKTEA NERLRRLAED QAAQHKADIE DSELERQKGL VEEEILALKA ELELELGRIR EQAELEAARQ RREAEERVQK QRKAALEEVE RLRERAEQES AQKRLQAEEK QELQQTLQQE AEAARRAAEE EAAQSRRQVE EQAQARAQAQ EQEAARRAQA ADAEMEKHKK QVEQELTTLR NLLDEELQRL RSQVEEELFS LKARIEAENR QRFLQEEAEK LSVAAQEAAR QQRALAEKML TRLKAEAELL ARRLQEDKEQ EVERWRERVA AQTDVRQREL RESADPLGAW IQAMPLADSQ ALLEEIERHG KQYINAIKDY LEPVASPAKK IQEYVDLRTH YIKFISETLR QQRAEERERL RQLAEAHAQA LQQRMQEEW QQKRSIQEEL IQAKARQAEA EIRVVRLQLE GELQALRARA QEEAERLRRQ AEVELASRVK RALQALEELR RQAEVERARQ SAEAELQSKR ERSLQEEHVA RAQQQAEAER RWQLKANEAL QQKSLAQAEA ARRRGKAEEQ ELEKQRQLAE QELIRLRAET EEELARLQRE LEAELAKVRA RAEEESRSTS AGRFRELAEE AKRQRQLAEE RVLAEKLAAI EIALKEKEAE EAFQRRRLEE ERLAQLRKAS VEDTLRQRRQ SFEKAAAGKA SNAEDTLRSK RQLAAEEERR SLAAEEEAAR RLKAKVEEAR ARQLQLAQEA AHAFAVQQKE QSVLDQLRGE AEEARVQAER EAERLKQSAE AAAEKLRKEA EQAALRQKQA FAEQTLRQKA LQLEETDHQK KAEATEAARQ VRVQMEELSK ALILRDKDNT MKQVAEEAAR LRQLAEEDLA KEKMQAVQEA QQQKELAQEQ MAQQLAEETQ GFQRTLEAER ERLKLRVAEM AQRFRKQAEE ATQEKVTLVQ HDAERLREAI QQEAKLLQLK QLLQETQALQ LQRERFIEQE EVAKAQQLRE QERQRLVASM EEGVRRKQEE QEELLAEENQ EQHRAALAHS TKTLPNGRDA EHSFDGLRRK ILSAEELQRL ARREDVRHYL LKATNEKLSV PGTALILLEA VRNRRLTVNE LHHKLLSAER GQQISLFQAM IRLLEAQIAT RVPVDVAYRR LADPSDDTKG TYLQLLERCV PLTDKAAKGG DVFEKATVSA TIWEIINSEY RQFRTGRITV VEEQEQKGRL AAELLESRVI GERSVRDVAE ANVIAGVWLE ALKKDLLPSD GTGHIIDPAT RAGLVGPEFH TGYRDPYTGQ GLIPREQGLR IVDPSKSHRV LDEETSRALS DPSTGEPATY QLTGLSLLPL ELYSELQARE VGGFKGRTVT TAEQRQELLR KVIKILITIV LSFSGLRAPV LSRAQFEQLK ELGSVRTLLQ EDTKEKVSIY TTAALLLEAQ RNQRLYVHEA HEQLLSAEKA STISLFQAMQ RLLEAQIATG VPVDVAYQRG ADPSDDTKGF YRQLLERCVE LKGAEKAEW QRQLEMSAEA SRAQARAEED IGEKLHRTEL TLEIQRQQSD AELEREKEKL SEEMQTVQQE QSFLSEKDSL KAKLEQLFQD EQQRQQQQME EEARRRQHEA LQQLEQQRRQ RLREQLQLLE EEVTASQVAA LDGPAAEAEP VSAQRLQEAG AQGHTTVDEL QGRSSIAGLL YAALQRQLLS QAASGFLLDP AVKEGVVGPE AVTGYKDPYT QKGLIVREHG GGVIDPVHSH GYFDEEMNRV FFDPNTHENL EDPETGLCLL ELVYTDSEAR PFGKFQGKTV FTAEQRRDLL EKIIKIIITV CFEGLRSLVP DRELYQQLQR VDTVRRALRG EAGQKLSIYN MAVALLEAQA SARLTVDEAV EKLLSAEKAV SVSLFQALKK LLDAQLSTGG PLDVACARGC APRADAKAYS GELQQRCRPD SEKAARARQE TFEKTPVEVP VWELISSEYF QFRTGKVTVE EEVETLRQER PASELLASGV DGKTTVKDLS GSGCLAGIYL EAMRRGLLRA AATGFLVDPV VKAGVVGPEL VTGYRDPYSG KGLVLRQHGI GIIDPVHSHR YFSEEMNRVL FDPNTHENLT DPETGLRLLP ETTQVYTEEE TRRAFEETQI STMSLWEVMQ QLMADFQAGR IEIIEKTEII VRRRLTAEDL YNLLREGTRS WCYLYGTGSV TLSIYQALKK LLEAQAATGF TVDEAVRKGL SAERAVTGYR FQAMKKELIP QLATGGIVDP AYQRGYLNKD VRSYVDPSTD RCRRDDGTGQ LTFRGLRKQI MDEATALQLR KNLQKFLEGT TKERLSVYQA AFELLEAQAA LKLTVEEAVR KLLSAERAVT ISLFQAMKKG LEAQIATGGI VEVAYKRGLF PSDDTKGFFD QLMERCITDP EKKRERKTSS IVDPETGKEM IDHQTYLELS ISSSDGVVKS YDIDDAIAKN RAGTLSITEF FRSRSSSVGS SRTQLASWSD ILDTETLEKV VDNITGQRLL DPSTGERFPV KIMVDRINLA RTKTKMSAAQ AGQRFLEVQY PGRVPLDEAL QKLRDVGAYS KISYKDALDR LLEAAAQSTK SGSTAGSRTG FSMTFSSSSY SSSGYGRRYA ESAVA DIPGGGSHGG SDLIPEEQRA VTKERMIIII RQQGLASYDY FEARIISLET LREALEAESA AGVYLPGSRQ GLLSAEVARL LLDPVKGERL VGPELHDRLL DPYTEQTISL TEEALRLLDA RLGFHLPLEV THDQLSEPSE ERLSYTQLLR LLLPLSDARK TMEELVRSQV EGLTSIEEVT SCIAGVFVDA MKKGIIRPGT TGYVIDPIKG MGIVGPEFKD GYKDPYSGKL LILKDHGIRL IDPEESHRLP DEEMNEILTD PNTEENLTYL QTGLCLLPLK KSSVRKRRVV SVYEAYRKGL EQECEWEEIT MIIDRRSGRQ LIDRSALDQY ADMLSGNAGG SSSYPISPAV PTEETGPVAG SITEAMHRNL EAQACTGGII TDAVNKGLVD QKAFCGFEDP ALKKGWLYYE LTGGLIEPDT QRGTVDARTA KYLTCPKTKL SMVEEGTGLR GYYSPYSVSG SRTGSRAGSR RGSFDATGSG SGSSASLGGP 75 PLEC 9 Q151499 Entry version 224 (18 Sep. 2019) Sequence version 3 (14 Oct. 2008) MAGPLPDEQD KYKDERDRVQ HLIKAQRHIS NLISLLEVLS MRFHKLQNVQ VKLVNIRNDD GLIWTIILHF SEDMTAKEKL YQGLRCDNFT AIIHRHKPLL FIQAYEEVRE KKTFTKWVNK DLYEDLRDGH GDSLPREKGR IALDYLRHRQ IADGNPKLTL QISDIQVSGQ LLWSQRMVEG SSWRDGRLFN IDMNKVYRQT NLENLDQAFS LLDPEDVDVP VSSLYDAMPR NELQLRWQEY MRHHTAAFEE EILWSQFLKF DKNRSKGIYQ LKVPPGYHPL VAILEREKQL QRIVTKLQME ADALLQSDVR AGEVERDLDK DVQTLKDGRH YRLHERLVAI GVAAPATQVA PELEDSTLRY NQHRVDGAEW LGSHRGLHQS ARSDEGQLSP GRLDLQYAKL LESLHSFVAA KEEEEVGFDW KESYSALMRE LQNAGDRLLR SFQAALQTQW EAHLKENAAY EGQLQKLQEA ATVTRLEDLL NEYKGHLSGL KPRHPAHPMR YKQVEVTVHK QPSHWKVLSS CFLVPPPNQE QHQALVTLWH AWQSLRRDVQ RTLKPEEQRQ AFLRDSQDAG EREYGSCSHH GAQEESRCQR QLEACETRTV PARECAQRIA GLGKGVARLS EPSPAAPTLR EQVRSLSAIY IRGTQGAEEV AQAVPATLPE LRAQAEAQQP GAQEVGERLQ ERWRERVAQL TDVRQRELEQ SADPLGAWLQ AMPLADSQAV LEEIERHGEK YINAIKDYEL PVASPAKKPK EYVDLRTHYS KFISETLRRM RAEERERLAE LAEAHAQAKA QRMQEEWRR VAERDLGVTR QPDEKSIITY VPDVQDGVRA RELVLLLLQW RRFPSSFEEI KEMELPAKEA SLEGAVQAGQ DVEKEWGKLH RSEFERLECL AGLCEEQLNQ LLAAGKVPQR ADSMIRLLFN PQGEQMYRRV RTEYNLRLKA QVTLQSVQRR LQDLLAWVEE GVDLPSVEAQ IEEFRAKIER ATRGAYRDCL LNSSKARLRS ATKELMWLNE SDRNTNMTAK LELKEKKIKE EDHPARPTVE SWMLQLCCCI FQFFSDVREA LRRKYSCDRS QDAQDEKEQL AKRAKAVVQL GRLPLLAVCD GDECQLVGPA SGSEAAVPSV AQEAVTRLEA QLHVDMKSLL LIRSWSLATF ALHSLELHYQ GFGPEDRLMA YQQLLQSLEQ CISELKDIRL HRLRLPLDKE EQQKAQAEVE AEAEKVLALP SELELTLGKL LEKLKTISLV LRAHEEQLKE LEATKASLKK TFDALRDELR QRHGERDVEV LERWQAVLAQ LGRQLRYYRE DARRRQEQIQ REQLRQEQAL VEECQRFAKQ QLVTYKAQLE VQSGSESVIQ ELTTLTSQYI EEEERLAEQQ VEAALEKQRQ QAEREAKELQ EEAAVDAQQQ KRSIQEELQQ AKARQAEAAE RVVRLQLEAT LQALRARAEE EAERLRRQVQ VELASRVKAE LQALEELRLQ AEVERARQVQ EAELQSKRAS SLQEEHVAVA QQQAEAERAR QLKANEALRL KSLAQAEAEK RRGKAEEQAV EKQRQLAEGT LIRLRAETEQ ELARLQREAA AELAKVRAEM EEESRSTSEK RFRELAEEAA RQRQLAEEDA LAEKLAAIGE ALKEKEAENE FQRRRLEEQA LAQLRKASDS DTLRQRRQVE EKAAAGKAEL AEDTLRSKEQ LAAEEERRRR AAEEEAARQR KAKVEEARRL QLQLAQEAAQ AFAVQQKEQE VLDQLRGEAE EARVQAEREA ERLKQSAEEQ AEKLRKEAEQ AALRQKQAAD EQTLRQKAQV LEETDHQKNL EATEAARQRS VQMEELSKLK ILRDKDNTQR QVAEEAARLS QLAEEDLAQQ RALAEKMLKE QKELAQEQAR QQLAEETQGF QRTLEAERQR AQARAEEDAQ EKLHRTELAT EIQRQQSDHD LEREKEKLQQ EMQTVQQEQL FLSEKDSLLQ KLEQLFQDEV QRQQQQMEQE ARRRQHEAEE QLEQQRRQQE REQLQLLEEQ LRQSSEAEIQ RSRLRIEEEI ERQRGGAEGE AEAQKRQAQE DESQRKRQAE AEAAREKQRA AEEAERRLRQ VALETAQRSA FAEKTAQLER QLREEAERRA EEAERELERW RLQAEEVAQQ QKEEAEREAR RQRELAEQEL AQQRLAAEQE GEQQRQLLEE AATQKRQELE EVLLASKARA SKQRLEAEAG RLRALAEEAK ARQRAEAERV ATRLKTEAEI RLRRLAEDEA AQHKADIEER ELERQKGLVE EEILALKASF ELELGRIRSN AELEAARQRQ EAEERVQKSL KAALEEVERL RERAEQESAR KRLQAEEKAH LQQTLQQEQS AARRAAEEAE AQSRRQVEEA AQARAQAQAA EAARRAQAEQ AEMEKHKKFA EQELTTLRLQ LDEELQRLKA QVEEELFSVR ARIEAENRAL FLQEEAEKMK VAAQEAARLR KMQAVQEATR LKAEAELLQQ RLQEDKEQMA QLEMSAEAER LKLRVAEMSR RFRKQAEEIG QEKVTLVQTL AERLREAIAE EAKLLQLKSE LQETQALQQS RERFIEQEKA AKAQQLREEQ RQRLVASMEE GVRRKQEELQ ELLAEENQRL HRAALAHSEE VTASQVAATK GPAAEAEPEH AQRLQEAGIL GHTTVDELAR RSSIAGLLLK ALQRQLLSPG ASGFLLDPVR KEGVVGPELH TGYKDPYTGQ GLIVREHGIR VIDPVHSHRV FDEEMNRVLA DPNTHENLTY PETGLCLLPL VYTDSEARDV GKFQGKTVTI AEQRRDLLRQ IIKIIITVVE EGLRSLVPAA ELYQQLQRGE TVRRALRGAN GQKLSIYNAL VALLEAQAGT RLTVDEAVRA LLSAEKAVTG SLFQALKKGL DAQLSTGGIV DVACARGCLD RADAKAYSDP LQQRCRPDQL KAARARQEEL EKTPVEVPVG ELISSEYFTA RTGKVTVEKV VETLRQERLS SELLASGVLS KTTVKDLSEL GCLAGIYLED MRRGLLRATT TGFLVDPVRN AGVVGPELHE GYRDPYSGST LVLRQHGIRL IDPVHSHRVP SEEMNRVLAD PNTHENLTYR ETGLRLLPLK TQVYTEEETR PGGGSHGGST LIPEEQRAQL KERMIIIIIE QGLASYDYVR ARIISLETYN EALEAESAWC VYLPGSRQTL LSAEVARLLL DPVKGERLTV PELHDRLLSA YTEQTISLFQ EALRLLDAQL TLPNGRDALD SFDGLRRKVS SAEELQRLAQ REDVRHYLQG ATNEKLSVYA TALILLEAQA NRRLTVNEAV HKLLSAERAV QISLFQAMQK LLEAQIATGG PVDVAYRRGY DPSDDTKGFF LQLLERCVED TDKAAKGGEL FEKATVSAPF WEIINSEYFT FRTGRITVEK EQEQKGRLCF ELLESRVIDR RSVRDVAEVD VIAGVWLEEA KKDLLPSDMA GHIIDPATSA GLVGPEFHEK YRDPYTGQSV IPREQGLRLL DPSKSHRVPL EETSRALSAP STGEPATYGE TGLSLLPLSE YSELQARETF GFKGRTVTVW EQRQELLRQF IKILITIVEE FSGLRAPVPA RAQFEQLKDG GSVRTLLQGS TKEKVSIYEA AALLLEAQAA QRLYVHEAVK QLLSAEKAVT ISLFQAMQKG LEAQIATGGI VDVAYQRGYF PSDDTKGFFD QLLERCVEDP GAEKAEVVET RAFEETQIDI MSLWEVMQSD MADFQAGRVT IIEKTEIIRQ RRLTAEDLFE LLREGTRSLR YLYGTGSVAG SIYQALKKGL EAQAATGFLL DEAVRKGLVG ERAVTGYRDP AMKKELIPTE ATGGIVDPRL GFHLPLEVAY DQLSEPSEVR LSYTQLLRRC LPLSDARKLT EELVRSQVMD LTSIEEVTKN IAGVFVDATK KGIIRPGTAF YVIDPIKGLK IVGPEFKDKL KDPYSGKLIS LKDHGIRLLE PEESHRLPVE EMNEILTDPS TEENLTYLQL GLCLLPLKEK SVRKRRVVIV YEAYRKGLID ECEWEEITIS IDRRSGRQYD DRSALDQYRA MLSGNAGGFR SYPISPAVSR EETGPVAGIL TEAMHRNLVD QACTGGIIDP AVNKGLVDKI AFCGFEDPRT KKGWLYYEAG GGLIEPDTPG GTVDARTAQK LTCPKTKLKI VEEGTGLRLL YSPYSVSGSG TGSRAGSRRG MTFSSSSYSS SSASLGGPES QRGYLNKDTH SYVDPSTDER RRDDGTGQLL FRGLRKQITM EATALQLREG LQKFLEGTSC ERLSVYQAMK ELLEAQAATG LTVEEAVRMG LSAERAVTGY LFQAMKKGLI AQIATGGIID VAYKRGLFDE DDTKGFFDPN MERCITDPQT KRERKTSSKS DPETGKEMSV HQTYLELSEQ SSDGVVKSMI IDDAIAKNLI GTLSITEFAD SRSSSVGSSS TQLASWSDPT DTETLEKVSI NITGQRLLEA STGERFPVTD MVDRINLAQK KTKMSAAQAL QRFLEVQYLT RVPLDEALQR LRDVGAYSKY SYKDALDRSM EAAAQSTKGY STAGSRTGSR SFDATGSGFS SGYGRRYASG AVA 76 ACSLI 1 P33121 Entry version 186 (18 Sep. 2019) Sequence version 1 (01 Oct. 1993) MQAHELFRYF YVRTLPTNTL LKPPCDLSMQ SVEVAGSGGA PLVYFYDDVT QVSNNGPCLG LSYKQVAELS GFKTAPDQFI VIIEQGCFAY LGNEAITYIV DKPEKAKLLL LKIIVVMDAY CGVEVTSMKA KPKPPAPEDL GNPKGAMVTH VKATENTVNP PLAHMFERVV IGFFQGDIRL TVFPVVPRLL ANTTLKRWLL LRSGIIRNNS QSSLGGRVRL TVLTFLRAAL RMPELVDFRQ MGFGAFAALT TFWYATRPKP RRSALLDSDE TLYEGFQRGI SRKPDQPYEW ECIGSALIQK GIFAQNRPEW SMVIVPLYDT NKAELSLVFV EGVENKLIPG GSELVERGQR MEDLGRANRR AVICFTSGTT RNIVSDCSAF CPDDTLISFL ECVMLCHGAK LMDDLKVLQP NRMFDRIFGQ DFASKRKEAE LWDRLIFHKV MVTGAAPVSA GCQFYEGYGQ TECTAGCCLT GAPMPCNLIK AAEGEGEVCV KDPAKTAEAL IGKWLPNGTL KLAQGEYIAP EPVAQVFVHG VVPDVETLCS FEELCRNKDV LGKDSGLKPF ELFSIDNGLL LRNYFRSQID MPGDWTAGHV LVDVEEMNYM KGPNVFQGYL DKDGWLHTGD KIIDRKKHIF EKIENIYMRS ESLQAFLIAI WAQKRGFEGS KKAILEDMVR EQVKGITLHP TPTMKAKRPE DLYSTIK 77 ACSLI 2 P331212 Entry version186 (18 Sep. 2019) Sequence version 1 (01 Oct. 1993) MQAHELFRYF YVRTLPTNTL TFWYATRPKP SVEVAGSGGA PLVYFYDDVT QVSNNGPCLG LSYKQVAELS GFKTAPDQFI VIIEQGCFAY LGNEAITYIV DKPEKAKLLL LKIIVVMDAY CGVEVTSMKA KPKPPAPEDL GNPKGAMVTH VKATENTVNP PLAHMFERVV IGFFQGDIRL TVFPVVPRLL ANTTLKRWLL LRSGIIRNNS QSSLGGRVRL TVLTFLRAAL TECTAGCCLT GAPMPCNLIK AAEGEGEGYL DKDGWLHTGD KIIDRKKHIF EKIENIYMRS ESLQAFLIAI WAQKRGFEGS KKAILEDMVR EQVKGITLHP TPTMKAKRPE DLYSTIKV RMPELVDFRQ MGFGAFAALT LKPPCDLSMQ RRSALLDSDE TLYEGFQRGI SRKPDQPYEW ECIGSALIQK GIFAQNRPEW SMVIVPLYDT NKAELSLVFV EGVENKLIPG GSELVERGQR MEDLGRANRR AVICFTSGTT RNIVSDCSAF CPDDTLISFL ECVMLCHGAK LMDDLKVLQP NRMFDRIFGQ DFASKRKEAE LWDRLIFHKV MVTGAAPVSA GCQFYEGYGQ MPGDWTAGHV LVDVEEMNYM KDPAKTAEAL IGKWLPNGTL KLAQGEYIAP EPVAQVFVHG VVPDVETLCS FEELCRNKDV LGKDSGLKPF ELFSIDNGLL LRNYFRSQID 78 ACSLI 3 P331213 Entry version 186 (18 Sep. 2019) Sequence version 1 (01 Oct. 1993) MQAHELFRYF YVRTLPTNTL TFWYATRPKP SVEVAGSGGA PLVYFYDDVT QVSNNGPCLG LSYKQVAELS GFKTAPDQFI VIIEQGCFAY LGNEAITYIV DKPEKAKLLL LKIIVVMDAY CGVEVTSMKA RMPELVDFRQ MGFGAFAALT LKPPCDLSMQ RRSALLDSDE TLYEGFQRGI SRKPDQPYEW ECIGSALIQK GIFAQNRPEW SMVIVPLYDT NKAELSLVFV EGVENKLIPG GSELVERGQR MEDLGRANRR KPKPPAPEDL GNPKGAMVTH VKATEKALPL PLAHIYEQLL IGFFQGDIRL TVFPVVPRLL ANTTLKRWLL LRSGIIRNNS QSSLGGRVRL TVLTFLRAAL TECTAGCCLT GAPMPCNLIK AAEGEGEVCV KDPAKTAEAL IGKWLPNGTL KLAQGEYIAP EPVAQVFVHG VVPDVETLCS FEELCRNKDV LGKDSGLKPF ELFSIDNGLL LRNYFRSQID AVICFTSGTT RNIVSDCSAF SASDTHISYL KCVMLCHGAK LMDDLKVLQP NRMFDRIFGQ DFASKRKEAE LWDRLIFHKV MVTGAAPVSA GCQFYEGYGQ MPGDWTAGHV LVDVEEMNYM KGPNVFQGYL DKDGWLHTGD KIIDRKKHIF EKIENIYMRS ESLQAFLIAI WAQKRGFEGS KKAILEDMVR EQVKGITLHP TPTMKAKRPE DLYSTIKV 79 RAC1 1 P63000 Entry version 192 (18 Sep. 2019) Sequence version 1 (31 Aug. 2004) MQAIKCVVVG ISYTTNAFPG SANVMVDGKP QEDYDRLRPL CFSLVSPASF VRHHCPNTPI DDKDTIEKLK QGLAMAKEIG TQRGLKTVFD PVKKRKRKCL DGAVGKTCLL EYIPTVFDNY VNLGLWDTAG SYPQTDVFLI ENVRAKWYPE ILVGTKLDLR EKKLTPITYP AVKYLECSAL EAIRAVLCPP LL 80 RAC1 2 P630002 Entry version 192 (18 Sep. 2019) Sequence version 1 (31 Aug. 2004) MQAIKCVVVG ISYTTNAFPG SANVMVDGKP QEDYDRLRPL GKDITSRGKD FSLVSPASFE RHHCPNTPII DKDTIEKLKE GLAMAKEIGA QRGLKTVFDE VKKRKRKCLL DGAVGKTCLL EYIPTVFDNY VNLGLWDTAG SYPQTVGETY KPIADVFLIC NVRAKWYPEV LVGTKLDLRD KKLTPITYPQ VKYLECSALT AIRAVLCPPP L 81 PSMB2 1 P49721 Entry version 201 (18 Sep. 2019) Sequence version 1 (01 Oct. 1996) MEYLIGIQGP AASNIVQMKD KILLLCVGEA QKNVQLYKMR ANFTRRNLAD NLLLAGYDEH LAALAKAPFA SILDRYYTPT RKCLEELQKR RIIDKNGIHD S DYVLVASDRV DHDKMFKMSE GDTVQFAEYI NGYELSPTAA CLRSRTPYHV EGPALYYMDY AHGYGAFLTL ISRERAVELL FILNLPTFSV LDNISFPKQG 82 GM2A 1 P17900 Entry version 190 (18 Sep. 2019) MQSLMQAPLL AQAHLKKPSQ EGKDPAVIRS IALGLLLAAP LSSFSWDNCD LTLEPDPIIV Sequence version 4 (13 Nov. 2007 PGNVTLSVMG KVDLVLEKEV DYIGSCTFEH TGEPCPEPLR KEGTYSLPKS SWLTTGNYRI LGCIKIAASL STSVPLSSPL AGLWIKIPCT FCDVLDMLIP TYGLPCHCPF EFVVPDLELP ESVLSSSGKR KGI

VARIANT GENE SEQUENCES

[0461] TABLE-US-00005 SEQ ID NO. GENE Accession No. Ensembl Release No. 83 CAP37 ENSG00000278624 98 84 TAPBP ENSG00000112493 98 85 TAPBP ENSG00000206281 98 86 TAPBP ENSG00000112493 98 87 TAPBP ENSG00000236490 98

EXAMPLES

Materials and Methods

Isolation of Stem Cell-Derived Neutrophils

[0462] Stem cell-derived neutrophils (SCDN) were synthesised according to standard techniques and cultured ex vivo for 25 days following Ficoll-separation to obtain PBMCs and CD34+ isolates from ten one-off donor buffy leukocyte cones. Aliquots of the SCDN (50 × 10.sup.6 /ml) were frozen at -80° C. in cryopreservative (10% FBS in DMSO).

Evaluation of Cancer Killing Activity (CKA) Using the xCelligence Assay

[0463] SCDN were thawed and decanted into complete Dulbecco’s modified Eagle’s medium (DMEM) before incubation for 72 hours with pancreatic cancer (PANC-1) cells and ‘healthy’ breast epithelial cells (MCF-12F) (commercially available from the American Type Culture Collection - United Kingdom (U.K.), Guernsey, Ireland, Jersey and Liechtenstein, LGC Standards, Queens Road, Teddington, Middlesex TW11 0LY, UK). CKA was recorded regularly throughout the 72 hour culture period by xCelligence Assay.

[0464] The ACEA Biosciences xCELLigence RTCA DP Analyzer system® was used and the manufacturer’s instructions were followed. The xCELLigence System is a real-time cell analyser, allowing for label-free and dynamic monitoring of cellular phenotypic changes continuously by measuring electrical impedance. The system measures impedance using interdigitated gold microelectrodes integrated into the bottom of each well of the tissue culture E-Plates. Impedance measurements are displayed as Cell Index (CI) values, providing quantitative information about the biological status of the cells, including viability. Impedance-based monitoring of cell viability correlates with cell number and MTT-based readout. The kinetic aspect of impedance-based cell viability measurements provides the necessary temporal information when neutrophils are used to induce cytotoxic effects. In particular, the xCELLigence System can also pinpoint the optimal time points when the neutrophils achieve their maximal effect (where such data is desired), as indicated by the lowest CI values, in cytotoxicity and cell death assays. 6,000 cancer cells (PANC-1) or healthy, non-cancerous cells (MCF-12F) are placed in the bottom of a 16 well plate (the system can read up to 3 plates simultaneously). For the first few hours after cells have been added to a well there is a rapid increase in impedance. This is caused by cells falling out of suspension, depositing onto the electrodes, and forming focal adhesions. If the initial number of cells added is low and there is empty space on the well bottom, cells will proliferate, causing a gradual yet steady increase in Cl. When cells reach confluence the CI value plateaus, reflecting the fact that the electrode surface area that is accessible to bulk media is no longer changing. At this point, which is called the ‘normalization point’, the neutrophils (60,000 cells) are added (giving a 10:1 effector:target ratio) and incubated at 37° C. The percentage of cytolysis is readily calculated using a simple formula: Percentage of cytolysis = ((Cell index.sub.no.sub.effector - Cell Index.sub.effector)/Cell Index.sub.no.sub.effector) × 100.

[0465] SCDNs that demonstrated >80% CKA (against PANC-1) by 48 hours after addition, and <10% off-target killing (i.e. killed <10% of ‘healthy’ breast epithelial cells (MCF-12F) by 48 hours after addition) were designated high CKA neutrophils and cells that demonstrated <51.5% CKA were designated low CKA control neutrophils.

Proteomic Analysis

[0466] Neutrophils were lysed and underwent sonication and were analysed using the Pierce bicinchoninic acid (BCA) protein assay according to manufacturer’s instructions (commercially available from ThermoFisher, Waltham, MA, catalogue number: 23225) to determine protein concentration. Typically samples contained around 20 micrograms of protein in <500 .Math.l. Samples were digested, desalted and lyophilised prior to liquid chromatography and mass spectrometry (LC-MS/MS) using a Thermo Q-Exactive (Orbitrap) Plus Mass Spectrometer (Thermo Scientific™). First, chromatography separates the peptides in solution, the smaller hydrophilic peptides come off the column in the first fraction, and bigger hydrophobic peptides come off last over a 2 hour period. Secondly, a strongly acidic pH2 solution ensures all peptides have protons and are thus given a positive charge, the Mass Spectrometer only allows through positively charged ions of a given fraction to hit the detector. The Orbitrap device fluctuates between isolate and fragment, at around 20 Hz so the least ‘sticky’ peptides of a given mass/charge ratio are quantified first. The fluctuations are proportional to the intensity of the peptides detected, thus providing protein quantities for each cell type.

[0467] Bioinformatics was performed using the online DAVID system (Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1-13.; and Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57).

Example 1

[0468] Proteomic analysis was carried out according to the Materials & Methods section herein. Advantageously, a number of proteins were significantly upregulated in the high CKA neutrophils when compared to low CKA controls.

[0469] The following proteins (and thus genes) were upregulated compared to low CKA controls: S100A9, S100A8, ITGB1, CYBB, SYK, DOCK8, COMP, ATG7, SLC2A1, GZMK, CTSG, ATM, IKBKB, BCAP31, TAPBP, PERM, PLEC, ACSL1, RAC1, GM2A, CAP37, and PSMB2.

[0470] The following proteins (and thus genes) were downregulated compared to low CKA controls: ANXA1 and PPP3CB.

[0471] Table 1 presents a number of proteins with changed expression in high CKA cells compared to the typical low CKA cells.

TABLE-US-00006 Protein log2 (High CKA/Typical) p-value (t-test) GM2A 1.943649 7.66E-06 PLEC 0.855651 0.000199 CYBB 1.609576 0.00024 DOCK8 1.454172 0.000455 ATG7 1.163505 0.000737 SLC2A1 1.4505 0.001259 S100A9 1.435349 0.001681 ACSL1 1.065324 0.001746 CTSG 2.155855 0.002295 PSMB2 1.058384 0.002481 ATM 2.011409 0.002754 BCAP31 2.707073 0.003322 S100A8 0.699763 0.003776 ITGB1 1.143777 0.005138 TAPBP 1.277103 0.005596 COMP 0.99287 0.005695 SYK 1.722188 0.006851 GZMK 1.8696069 0.040591 IKBKB 2.2958852 0.017181 PPP3CB -1.36037 0.000127 ANXA1 -1.17725 0.000792 PERM 2.00962408 0.0379030 RAC1 1.9456240 0.0100812 CAP37 2.70390702 0.01459156

[0472] The results are presented graphically in FIGS. 2-6 for a number of the proteins, including two-way ANOVA statistical analyses. Advantageously, said protein levels (and thus gene expression levels) provided a robust means for identifying and differentiating high CKA cells from low CKA cells.

[0473] Advantageously, the expression of many of the genes (i.e. at the protein level) was highly statistically-significantly different (e.g. GM2A) between high CKA cells and low CKA cells, indicating that high CKA granulocytes could be identified using just one of the indicated genes.

[0474] All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.